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ABSTRACT 
 
The importance of B cells and plasma cell in autoimmune diseases such as multiple sclerosis 
(MS) has been widely established in the last decades. The role of antibody producing plasma 
cells is crucial, as those cells may persist for extended periods as long-lived plasma cells. The 
survival of these plasma cells is closely regulated by B cell maturation antigen (BCMA), a 
membrane-bound receptor for its agonist ligands BAFF and APRIL that belong to the tumor 
necrosis factor superfamily. While the release of soluble endogenous receptors as regulatory 
mechanism is already well known for some TNFR-SF members, the generation of soluble 
BCMA (sBCMA) has so far not been described.  
Having identified by ELISA the presence of sBCMA in serum of healthy controls, the aim of 
this study was first to investigate the potential role of sBCMA as biomarker in B cell-
mediated autoimmune diseases such as multiple sclerosis and systemic lupus erythematosus 
(SLE). Further we aimed to characterize the source of sBCMA, the biochemical mechanisms 
behind the generation of sBCMA and the functional consequences of BCMA shedding. 
We observed that in MS, sBCMA levels in spinal fluid were elevated and associated with 
intracerebral IgG production; in systemic lupus erythematosus, sBCMA levels in serum were 
elevated and correlate with disease activity. Unexpectedly we found that sBCMA was directly 
shed from human Ig-secreting cells by γ-secretase. γ-secretase was previously found to cleave 
remaining fragments of membrane proteins only after their extracellular domain had been 
cleaved by another protease. It is also best known for processing of amyloid precursor protein 
(APP) and Notch. We thus demonstrated a novel function of γ-secretase, direct shedding of a 
membrane protein. By artificially extending the extracellular domain of human BCMA, we 
were able to show that its direct shedding is facilitated by the short length of BCMA’s 
extracellular domain. Further in vitro analysis showed that BCMA shedding limits the surface 
expression and ligand-binding of BCMA on Ig-secreting cells, and reduces ligand-mediated 
NF-κB activation. Moreover sBCMA blocked the activity of the ligand APRIL, acting as a 
decoy. Finally, to get further insights into the in vivo relevance of BCMA shedding, we used 
two different animal models: Ova/LPS-immunized C57/BL6 mice and a murine SLE model 
with spontaneous formation of germinal centers and plasma cells. Inhibition of the γ-secretase 
and BCMA shedding in these mice resulted in enhanced BCMA surface expression in plasma 
cells and in an increased number of plasma cells in the bone marrow.  
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Together, shedding of BCMA constitutes a novel immunoregulatory feed-back mechanism 
that limits a critical survival receptor on Ig-secreting cells and thus regulates the survival of 
plasma cells in the bone marrow. Moreover direct shedding of BCMA constitutes a novel 
function of γ-secretase. Finally, sBCMA itself could serve as a potential biomarker for B cell 
involvement in human autoimmune diseases.  
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ABBREVIATIONS 
 
ADAM  A disintegrin and metalloprotease 
ADEM  Acute disseminated encephalomyelitis 
APP  Amyloid precursor protein  
APRIL  A proliferation-inducing ligand 
AZA  Azathioprine 
BAFF  B cell activating factor of the TNF-family  
BAFF-R  BAFF-Receptor 
BCMA  B cell maturation antigen 
BM  Bone marrow 
BrdU  Bromodeoxyuridine 
CIS  Clinical isolated syndrome 
CLL  Chronic lymphocytic leukemia  
CNS  Central nervous system 
CSF  Cerebrospinal fluid 
CTF  C-terminal fragment 
CYC  Cyclophosphamide 
GA  Glatiramer Acetate 
GC  Germinal center 
GCS  Glucocorticosteroid 
HC  Healthy control 
HCQ  Hydroxychloroquine 
ICD  Intracellular domain 
Ig  Immunoglobulin 
ISC  Ig secreting cells 
mBCMA  Membrane bound BCMA 
MMF  Mycophenolate Mofetil  
MOG  Myelin oligodendrocyte glycoprotein 
MS   Multiple sclerosis 
NTF  N-terminal fragment 
NTZ  Natalizumab 
OCB  Oligoclonal band 
OND  Other neurological disease 
PBMC  Peripheral blood mononuclear cells 
PC  Plasma cell 
PCR  Polymerase chain reaction 
PEN-2  Presenilin enhancer 2  
PPMS  Primary progressive multiple sclerosis 
Pred  Prednisolone 
PS  Presenilin 
RRMS  Relapsing remitting multiple sclerosis 
sBCMA  Soluble BCMA 
SLE  Systemic lupus erythematosus  
SPMS  Secondary progressive multiple sclerosis 
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TACI  Transmembrane activator and CAML 
interactor 
TNF   Tumor necrosis factor 
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1 INTRODUCTION 
 
1.1 Multiple sclerosis  
 
The immune system features extremely efficient effector mechanisms that can eliminate a 
broad variety of pathogens. It is able to distinguish between the components of a healthy 
individual (the self) and external antigens (the non-self) resulting in immunological self-
tolerance. First described by Paul Ehrlich as “horror autotoxicus”, autoimmunity represents a 
breakdown or failure in the mechanisms of self-tolerance. In autoimmune diseases the 
immune response is activated by self-antigens or autoantigens and gives rise to autoreactive 
effector cells and to autoantibodies. This can lead to a variety of autoimmune diseases which 
are further classified into systemic autoimmune diseases, which affect multiple organs 
simultaneously such as SLE  and in organ-specific specific autoimmune diseases such as MS. 
MS is an autoimmune inflammatory disease of the central nervous system (CNS) and was 
first described in 1868 by Jean-Martin Charcot. The pathogenicity includes recurrent and 
acute focal inflammatory demyelinating lesions with axonal injury and astrocytic scar 
formation, resulting in intermittent neurological disturbance followed by progressive 
accumulation of disability (Compston and Coles 2008).  
The overall worldwide estimated number of people diagnosed with MS was approximately 
2.3 million in 2013, with the highest prevalence in North America and Europe (140 and 108 
/100.000 respectively). MS is as many other autoimmune diseases twice more common 
among women than men and the average age of onset is 30 years. MS still being an incurable 
disease, patients live with this progressive neurological disease for many decades. 
Depending of the lesion site, patients with MS can present with a variety of neurological 
deficits such as change in sensation, impaired balance and coordination, loss of vision and 
muscle weakness. The clinical course of MS is variable among patients and is classically 
divided in three subtypes, relapsing-remitting MS (RRMS), secondary progressive MS 
(SPMS) and primary progressive MS (PPMS). Approximately 85 % of MS patients begin 
with RRMS, a course of recurrent but mostly reversible neurological deficits where relapses 
can be followed by periods of month to years with no new signs of disease activity. SPMS is 
regarded as a common late stage of disease that follows RRMS after 8 – 20 years and is 
characterized by continuous and irreversible neurological disability unassociated with 
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relapses. PPMS is a less common form, only present in about 15 % of the patients, in which 
the disease progresses continuously from the beginning without any remission. 
Despite being the object of intensive research in the last decades, the initial cause of MS 
remains elusive. Linkage studies and genome-wide association studies (GWAS) have 
identified several susceptibility loci associated with MS, which are located in gene regions 
involved in immune system functions, in particular within the major histocompatibility 
complex (MHC) (International Multiple Sclerosis Genetics, Wellcome Trust Case Control et 
al. 2011). The relationship between environmental factor including sun exposure, vitamin D 
levels and infection by Epstein-Barr virus and MS remains debated (Ramagopalan, Dobson et 
al. 2010). 
 
1.2 Humoral immunity in MS  
 
T-cells have classically been considered the primary immune drivers in MS (McFarland and 
Martin 2007). However, this notion has recently been reassessed and the roles of B cells as 
well as the importance of the innate immune system have increasingly been recognized 
(Krumbholz, Derfuss et al. 2012). Evidences for the involvement of B cells and for the B cell 
fostering CNS environment in the pathogenicity of MS include: 
• Long-term persistence of intrathecal immunoglobulin (Ig) production with oligoclonal 
bands (OCB) present in more than 95% of MS patients (Freedman, Thompson et al. 
2005). 
 
• Presence of clonally expanded B cells located in the brain parenchyma and CSF 
responsible for the production of OCB (Owens, Ritchie et al. 2003; von Budingen, 
Gulati et al. 2010; Lovato, Willis et al. 2011; Obermeier, Lovato et al. 2011). 
 
• Memory B cells and plasmablasts are the predominating B-lineage cells in the CSF of 
patients with MS; their numbers correlate with disease activity (Krumbholz, Derfuss et 
al. 2012). 
 
• A detailed analysis of the white matter pathology in MS reveals four different lesion 
patterns (Lucchinetti, Bruck et al. 2000). Most interestingly, type II lesions show 
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immunoglobulin G (IgG) as well as active complement deposition present in the 
demyelinated areas of lesion type II. 
 
• Antibodies against conformationally intact MOG (Myelin oligodendrocyte 
glycoprotein) are very rare in adult MS patients, but occur in about one-fourth of 
patients with childhood MS and acute disseminated encephalomyelitis (ADEM) 
(Mayer and Meinl 2012). While Anti-MOG antibodies rapidly and continuously 
declined in patients with ADEM, longitudinal study noted the persistence of anti-
MOG IgG with fluctuations for a period of up to 5 years in children with MS 
(Probstel, Dornmair et al. 2011). More recently, the clinical and histopathological 
features of MOG-antibody-associated encephalomyelitis has been described (Spadaro, 
Gerdes et al. 2014). 
 
• Therapeutic efficacy of plasmapheresis and B cell targeting therapies such as 
Rituximab, Ocrelizumab (Bar-Or, Calabresi et al. 2008; Hauser, Waubant et al. 2008; 
Kappos, Li et al. 2011).  
 
Apart from their role as antibody producing cells, B cells can influence the inflammatory 
environment in general, as they produce both pro-inflammatory and anti-inflammatory 
cytokines and can serves as APC to T cells (Figure 1). 
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Figure 1. Proinflammatory and regulatory effects of B cells. B cells can develop into 
immunoglobulin-secreting plasma cells, efficiently present their cognate antigen to T cells, 
and secrete inflammatory cytokines that activate T cells and macrophages. B cells can also 
secrete cytokines that block T cells and macrophage activation. Abbreviation: LT, 
Lymphotoxin. (Krumbholz, Derfuss et al. 2012). 
 
1.3 Systemic lupus erythematosus 
 
Systemic lupus erythematosus (SLE) is an idiopathic, systemic autoimmune disease and is 
characterized by multisystem immune-mediated injury in the setting of autoimmunity to 
nuclear antigens. SLE most often harms the heart, joints, skin, lungs blood vessels, liver, 
kidney, and nervous system. The course of the disease is unpredictable, with period of illness 
(called flares) alternating with remissions. 
Although the initial cause of the disease remains unclear, there has been accumulating 
evidence for a key role of B cells, as initiating, amplifying and effector cells. The 
BAFF/APRIL pathway, in particular, is over-activated in SLE and plays an important role in 
the pathogenesis of the disease (Vincent, Morand et al. 2014). This became particularly 
evident when, in 2011, belimumab, a monoclonal antibody targeting human BAFF, was 
shown in randomized clinical trials to be efficacious in a subset of patients with SLE and has 
now become the first approved targeted therapy for SLE (Furie, Petri et al. 2011; Navarra, 
Guzman et al. 2011). 
 
1.4 The BAFF/APRIL-system 
 
1.4.1 Structure, expression and signaling of BAFF, APRIL and their receptors 
 
The cytokines B cell activating factor of the TNF-family (BAFF, also known as BLyS) and a 
proliferation-inducing ligand (APRIL) belong to the TNF ligand superfamily. BAFF and 
APRIL are initially synthesized as membrane-bound proteins and can be released as soluble 
forms by proteolytic processing at a furin consensus site (Moore, Belvedere et al. 1999; 
Schneider, MacKay et al. 1999). Both cytokines display the characteristic homotrimeric 
structure of the TNF family (Karpusas, Cachero et al. 2002; Wallweber, Compaan et al. 
2004). Soluble BAFF can further assemble as virus-like particles, forming a particle 
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containing 20 trimers (BAFF 60-mer). Proteoglycans are highly glycosylated O-linked 
glycoproteins that can be found as a soluble or membrane bound form. Soluble APRIL can 
bind to these proteoglycans. Remarkably, the proteoglycan-binding site of APRIL is distinct 
from the binding site of BCMA and TACI. The binding of APRIL to proteoglycans can 
therefore serve to concentrate APRIL, creating APRIL-riche niches, i.e. for plasma cells 
(Huard, McKee et al. 2008). Furthermore, an intergenic splicing between tweak and april 
genes generating TWE–PRIL, a hybrid ligand containing the full receptor-binding domain of 
APRIL, has been described (Pradet-Balade, Medema et al. 2002). 
BCMA, TACI and BAFF-R differ from the typical type I transmembrane TNF-receptors, 
which contain cysteine-rich domain (CRDs) in their extracellular domains. First, the three 
receptors are type III single pass transmembrane protein lacking a signal peptide. Further, 
while TACI contains two CRDs, BCMA has only one and BAFF-R has no CRDs. TACI can 
exist as two splice variants. While BAFF in its different forms can bind to all three receptors, 
APRIL binds to TACI and preferentially to BCMA (Figure 2). 
 
 
 
 
Figure 2. The BAFF and APRIL system. Red arrowheads indicate furin consensus cleavage 
sites. Glycosaminoglycan side chains of proteoglycans are shown as thick wavy red lines. 
Two splicing isoforms of human TACI differing in the presence or absence of the first 
cysteine-rich domain are depicted (Schneider et al. 2010)  
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BAFF and APRIL are mainly produced by innate immune cells (neutrophils, monocytes, 
dendritic cells and follicular dendritic cells). The receptors for BAFF and APRIL are mainly 
expressed by B cells (Figure 3). BAFF-R is largely expressed by all B cells except for bone 
marrow plasma cells. BAFF-R expression decreases and is eventually lost, as B cells 
differentiate into PC. TACI is found on memory B cells and on tonsillar and bone-marrow 
derived plasma cells. 
BCMA is mainly expressed by plasma cells, in lymphatic tissue and bone marrow. It can also 
be detected on tonsillar memory B cells. BCMA expression is induced as memory B cells 
differentiate into plasma cells (Darce, Arendt et al. 2007). Interestingly, BCMA expression 
inversely correlates with the loss of BAFF-R expression. Moreover, BCMA and TACI are 
also expressed by keratinocytes (Alexaki, Pelekanou et al. 2012). 
 
 
 
 
 
Figure 3. Surface expression of BAFF/APRIL-receptors during physiological B cell 
development modified from Krumbholz, Derfuss et al. 2012 
 
While BAFF can bind to all three receptors (BAFF-R, BCMA, and TACI), APRIL binds to 
TACI only and especially to BCMA with high affinity. Stimulation of BCMA and TACI 
activate the classical NFκB pathway stimulation. BAFF-R on the other hand can activate the 
alternative NFκB pathway and in weakly manner also the classical NFκB pathway 
(Hatzoglou, Roussel et al. 2000).  
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1.4.2 Physiological relevance of the BAFF/APRIL pathway 
 
1.4.2.1 B cell homeostasis and tolerance 
 
The cytokines BAFF and APRIL regulate multiple aspects of B cell functions and 
homeostasis. The pro-survival activity of BAFF was clearly shown by an almost complete 
lack of follicular and marginal zone B cells and by an impaired B cell maturation beyond the 
T1 stage in BAFF deficient and in BAFF-R deficient mice (Schiemann, Gommerman et al. 
2001; Shulga-Morskaya, Dobles et al. 2004). BAFF-R is considered a positive regulator of B 
cell homeostasis, because it transmits survival signals, whereas signaling through TACI 
decreases the size of the B cell pool (Mackay and Schneider 2008). It remains to be 
determined to what extent these findings in mice can be extrapolated to humans. 
The function of APRIL is not as well established as for BAFF. While one group reported 
intact B cell and T-cell development and in vitro function in APRIL knock-out mice 
(Varfolomeev, Kischkel et al. 2004), a second research group showed that APRIL-deficient 
mice, despite having T and B cell development and in vitro proliferation, presented with 
enlarged germinal centers and had an increase IgG response to T-cell dependent antigen 
(Castigli, Scott et al. 2004). Nevertheless, in both studies antibody class switch recombination 
was found to be impaired. 
 
1.4.2.2 Role of BCMA in plasma cell survival and antigen presentation 
 
Antibody producing cells, generated during a germinal-center reaction may persist for 
extended periods as long-lived plasma cells in survival niches in the bone marrow. This is the 
basis for persisting high affinity IgG against pathogens. Importantly, not only the bone 
marrow, but also inflamed tissues can provide a survival niche for plasma cells and thus 
constitute an efficient way of providing maximal amounts of specific antibodies at the site of 
inflammation (Radbruch, Muehlinghaus et al. 2006). In MS the inflamed CNS might act as a 
survival niche and promote survival of long-lived plasma cell, which would explain the 
persistence of OCB in the CSF of MS patients (Meinl, Krumbholz et al. 2006). Within those 
survival niches, BCMA is essential for the maintenance of long-lived plasma cells (Figure 4). 
This essential role of BCMA became evident through studies with BCMA (-/-) mice which 
displayed impaired survival of long-lived bone marrow PCs compared with wild-type controls 
(O'Connor, Raman et al. 2004). 
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The BCMA dependent maintenance of long-lived plasma cells seems to be largely mediated 
via its main ligand APRIL (Belnoue, Pihlgren et al. 2008; Benson, Dillon et al. 2008; Huard, 
McKee et al. 2008). In addition to its role in the survival of long-lived plasma cells, BCMA is 
also implicated in the regulation of antigen presentation activity of activated B cells (Yang, 
Hase et al. 2005). The authors showed that ligation of BCMA by APRIL resulted in the up-
regulation of surface molecules critical for Ag presentation such as CD40, CD80, CD86, 
MHC class II, and ICAM-1/CD54 and induced antigen presentation in splenic B cells.  
 
 
Figure 4. Plasma cell-surface phenotype and ligands in MS lesions. Central nervous system 
(CNS) resident cells (mainly astrocytes and microglia) produce mediators that promote the 
local survival of plasma cells. All of the displayed mediators are elevated in MS lesions. The 
corresponding receptors on plasma cells are shown. The cytokines B cell–activating factor of 
the tumor necrosis factor family (BAFF), A proliferation-inducing ligand (APRIL) and 
interleukin-6 (IL-6) promote plasma cell survival (Meinl, Krumbholz et al. 2006). 
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1.4.3 The BAFF/APRIL-system in autoimmunity 
 
1.4.3.1 In mice 
 
BAFF transgenic mice develop clinical and paraclinical features similar to SLE/Sjögren 
syndrome, with enlarged B cells compartments and lymphoid organs, high titers of dsDNA-
antibodies and rheumatoid factors. Hypergammaglobulinemia, circulating immune complexes 
and glomerulonephritis with immunoglobulin deposits were also detected (Mackay, 
Woodcock et al. 1999; Fletcher, Sutherland et al. 2006). Further studies showed that serum 
BAFF levels were elevated in a collagen-induced arthritis (CIA) mice model (Zhang, Park et 
al. 2005). Remarkably, the silencing of BAFF gene in those CIA mice prevented the 
development of autoimmune arthritis (Lai Kwan Lam, King Hung Ko et al. 2008). 
Autoimmunity in BAFF-transgenic mice is T-cell independent and Myd88 dependent 
(Groom, Fletcher et al. 2007). A possible explanation to these findings is that upregulation of 
BAFF expression in vivo would result in the rescue of self-reactive B cells from peripheral 
elimination (Thien, Phan et al. 2004).  
The role of APRIL remains certainly more unclear. Excess of APRIL leads to the 
development of B1 B cell lymphomas in APRIL-transgenic mice, but it does not cause 
apparent autoimmunity (Planelles, Carvalho-Pinto et al. 2004). However, increased 
production of APRIL was detected in lupus prone mice (NZB/W lupus mice) and selective 
antibody-mediated APRIL blockade in these mice delayed disease development (Huard, Tran 
et al. 2012).  
Exacerbation of disease in lupus-prone BCMA-deficient mice, suggests that BCMA has a 
direct or indirect negative regulatory role. In these mouse models, exacerbation of disease 
might occur by abnormal signaling of BAFF or APRIL through TACI or BAFF-R in the 
absence of BCMA (Jiang, Loo et al. 2011). 
 
1.4.3.2 In human  
 
The BAFF/APRIL pathway has been found to be constantly involved in various autoimmune 
diseases. 
In MS, BAFF expression was upregulated in CNS lesions; local production of BAFF by 
astrocytes in the inflamed CNS might promote survival of long-lived plasma cell, which 
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would explain the persistence of OCB in the CSF of MS patients (Krumbholz, Theil et al. 
2005).  
Serum concentrations of BAFF and APRIL are higher in patients with systemic lupus 
erythematosus (SLE) (Stohl 2003) and Wegener’s granulomatosis (Krumbholz, Specks et al. 
2005). The importance of BAFF in the pathogenesis of SLE became evident when in 2011, 
belimumab, a monoclonal antibody against human BAFF, became the first approved targeted 
therapy for SLE (Furie, Petri et al. 2011). As to the expression pattern of BAFF/APRIL 
receptors in SLE patients, BAFF-R expression on B cells was lower compared to healthy 
control B cells while BCMA expression was substantially increased on SLE B cells, 
especially on memory cells and plasmablasts (Kim, Gross et al. 2011).  
 
 
1.5 Soluble receptors 
 
1.5.1 Mechanisms of generations 
 
The production of soluble receptors, by attenuating or promoting cytokine signaling, 
constitutes an essential and evolutionary highly conserved regulatory mechanism of immunity 
and inflammation. These soluble receptors can be generated by various underlying 
mechanisms such as proteolytic cleavage of the ectodomain, alternative splicing and exosome 
release. These three mechanisms are not mutually exclusive (Heaney and Golde 1998).  
 
1.5.1.1 Shedding  
 
The proteolytic cleavage of the extracellular domain (also known as shedding) is typically 
catalyzed by a metalloproteinase of the ADAM (a disintegrin and metalloprotease) family, in 
particularly ADAM10 and ADAM17 (TACE). Amongst the large number receptor 
undergoing proteolytic cleavage, notorious examples include TNFR1, TNFR2, CD30, CD40, 
and IL-6Rα. TNF-receptor superfamily. In the case of type I oriented proteins the γ-secretase 
complex may further cleave the remaining fragment within the plasma membrane (Fluhrer 
and Haass 2007). 
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1.5.1.2 Alternative splicing 
 
The second important mechanism for the generation of soluble receptors is the alternative 
splicing of mRNA transcripts which deletes the transmembrane domain, thus giving rise to 
soluble receptors that contain signal peptides and lack transmembrane domains. The receptors 
are therefore secreted, rather than membrane-associated proteins. Soluble forms generated by 
alternative splicing of TNFR2, IL6-Rα, sFAS and most recently TNFR1 have been described 
(Gregory, Dendrou et al. 2012). 
 
 
1.5.1.3 Exosomes 
 
Exosomes are membranous vesicles of endocytic origin (diameter between 40–100 nm) that 
are released by different cell types into the extracellular space. The exosome-associated 
receptors can thus act as soluble receptors. For example, a full-length TNFR1 receptor 
associated to exosome-like vesicles and able to bind TNF-α has been reported to be 
constitutively generated by human vascular endothelial cells (Hawari, Rouhani et al. 2004). 
 
1.5.2 Functional relevance 
 
The conserved existence of soluble receptors and the complex regulation of their production 
and function suggest that they have an important role in normal physiology, with multi-
facetted consequences.  
Firstly, generation of soluble receptors by proteolytic cleavage leads to a down-modulation of 
the number of receptors on the cell surface, thus preventing signal generation by ligand. 
Second, provided that the shedded extracellular domain can still bind its ligand, the generated 
soluble receptor can become a decoy receptor. In this model, the soluble receptor acts as a 
non-signaling decoy competing with the membrane-bound receptors for ligand binding 
(Figure 5). In addition, the soluble receptor can serve as a binding protein that prevents its 
ligand from further degradation or clearance, as in the case of growth hormone receptor (GH-
BP). More rarely, soluble receptors associate with membrane-bound subunits to influence 
signal transduction, as is seen among the IL6 family of receptor. In the case of IL-6R, the 
complex formed by sIL-6Rα and IL-6, can bind to a membrane-bound signal transducing 
subunit (gp130) located on cells which do not express IL-6R (and would thus be unresponsive 
to IL-6). This pathway is referred to as trans-signaling (Rose-John 2012). 
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Figure 5. Mechanisms of actions of soluble receptors. (A) Generation of soluble receptors 
by proteolytic cleavage downmodulates number of membrane-bound receptors and prevent 
signal generation by ligand. (B) Soluble receptors as decoy receptors compete with 
membrane-bound receptors for ligand binding resulting in decreased receptor mediated 
signal generation. 
 
 
 
1.6 The γ-secretase complex 
 
The γ-secretase, a protease that cleaves within the membrane, has long been of particular 
interest to Alzheimer’s disease research for its role in the production of amyloid beta (Aß). 
The γ-secretase has the ability to cleave various type I membrane protein after these have 
undergone ectodomain shedding. The remaining stub can then be further processed by the γ-
secretase. This process is known as regulated intramembrane proteolysis (Figure 6), in which 
a membrane protein undergoes two consecutive cleavage by two distinct proteases controls 
the communication between cells and the extracellular environment (Lichtenthaler, Haass et 
al. 2011).  
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Figure 6. Schematic representation of regulated intramembrane proteolysis. A membrane 
protein undergoes two consecutive proteolytic cleavages by two distinct proteases (shown in 
blue). First, a membrane-bound protease cleaves close to the transmembrane domain, 
resulting in shedding of the ectodomain. The remaining membrane-bound fragment is further 
cleaved by an intramembranous protease. A small peptide is secreted into the 
luminal/extracellular space and the intracellular domain (ICD) is released into the cytosol, 
where it may either be further degraded, or participate in cytosolic signaling reactions or 
translocate to the nucleus and stimulate transcriptional activation of target genes. Regulated 
intramembrane proteolysis substrates are mostly single span membrane proteins. The 
membrane is represented as a grey box (Lichtenthaler, Haass et al. 2011). 
 
 
1.6.1 Subunits and assembly 
 
Over the years, biochemical and genetic approaches have identified four components of the γ-
secretase complex, presenilin, nicastrin, anterior pharynx defective homolog 1 (aph-1), and 
presenilin enhancer 2 (pen-2) (Figure 7). Within the γ-secretase complex, presenilin is the 
catalytically active subunit and undergoes endoproteolysis upon maturation to form a stable 
NTF/CTF complex. Nicastrin undergoes a glycosylation/maturation process, which is crucial 
for the assembly and maturation of the γ-secretase complex and gamma-activity (Shirotani, 
Edbauer et al. 2003; Chavez-Gutierrez, Tolia et al. 2008). 
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Figure 7. The components of the gamma-secretase complex. Presenilin, which is 
endoproteolysed during its maturation, contains the catalytic aspartyl residues. Nicastrin, 
APH1 and PEN2 are important for the maturation and trafficking of the complex (Kopan and 
Ilagan 2004). 
 
 
1.6.2 The role of γ-secretase in biology and disease 
 
Amyloid beta (Aβ) peptides are generated by the amyloidogenic pathway of amyloid 
precursor protein (APP) processing. APP, a transmembrane protein, is cleaved by α- or β- 
secretases, generating large, soluble, secreted fragments and membrane associated carboxy-
terminal fragments (CTFs). Aβ peptides could vary in size, from 38 to 43 aminoacids. The 
predominant isoforms are Aβ40 (90%) and the more fibrilogenic Aβ42 (10%).  They are 
generated after β-secretase (also known as BACE1, β-site APP cleaving enzyme) cleavage, 
followed by γ-secretase cleavage. Aβ peptide has the ability to auto-aggregate, so it can exist 
as monomers, dimers or oligomers; which in turn can generate fibrils that have β-sheet 
structure, and can deposit to form extracellular plaques (neuritic plaques). These processes are 
believed to be implicated in the pathogenesis of Alzheimer and in particular in the 
pathogenesis of familial Alzheimer’s disease cases.  
In addition, the role of the γ-secretase in the Notch signaling pathway is especially crucial and 
conserved. In the Notch pathway, binding of the Notch ligand to its receptor induces Notch 
signaling by releasing the intracellular domain of the Notch receptor through a cascade of 
proteolytic cleavages by TACE and γ-secretase. The released intracellular domain of Notch 
then translocates into the nucleus where it can further modulate gene expression (Schroeter, 
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Kisslinger et al. 1998; De Strooper, Annaert et al. 1999). In cancers, molecular genetic 
alterations are responsible for constitutive activation of Notch pathway, which all result in 
increased levels of intracellular Notch-IC. Since the Notch signaling pathway is a critical 
component in the molecular circuits that control cell fate during development, aberrant 
activation of this pathway can contribute to tumorogenesis. 
Over the past decades, inhibitors for γ-secretase have been actively investigated for their 
potential to block the generation of Aβ peptide in Alzheimer disease as well as for their 
antitumor effects (i.e. hematological malignancies, melanoma, breast cancer) with limited 
benefit so far. 
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2 OBJECTIVES  
 
We aimed at identifying features of humoral immunity that might be altered in autoimmune 
diseases. Maturation and survival of B cells and plasma cells is largely regulated via the 
ligands BAFF and APRIL with their receptors BCMA, BAFF-R and TACI. This dissertation 
focuses on BCMA, which regulates the survival of plasma cells. Having identified the 
presence of a soluble form of BCMA in serum of healthy controls, we aimed to characterize 
five major aspect of this novel soluble receptor.  
1) Is sBCMA a potential biomarker in autoimmune diseases with a B cell involvement (MS 
and SLE)? 
2) Which cells release sBCMA and how is this release regulated? 
3) What is the biochemical mechanism behind the generation of sBCMA? 
4) What is the functional consequence of BCMA shedding for the BCMA expressing cell? 
5) What is the function of sBCMA? 
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3 MATERIALS AND METHODS 
 
3.1 Materials  
 
3.1.1 Clinical samples 
 
Plasma and the corresponding CSF from 37 untreated patients diagnosed with either clinical 
isolated syndrome (CIS, n=10) or MS (n=27) and from 20 untreated patients with other 
neurological diseases (OND) as well as CSF pairs from 25 additional MS patients before and 
about one year after continuous natalizumab therapy were provided by Prof. Dr. Tomas 
Olsson and Dr. Mohsen Khademi. 5 CSF samples from neuroborreliosis patients were given 
by Prof. Dr. W. Pfister (Department of Neurology, Universitätsklinikum Großhadern, 
Munich, Germany). Longitudinally sera samples of 10 patients with MS who were treated 
with high doses of steroids (1000 mg/d methylprednisolone i.v. for 3-5 days) due to a relapse 
were provided by Prof. Dr. Frank Weber. Samples were obtained directly before treatment, 3 
days and 4 weeks later. Serum samples from 17 untreated and 22 treated SLE patients came 
from Prof. Dr. Falk Hiepe. The treated group included patients treated with 
glucocorticosteroid, hydroxychloroquine, azathioprine, cyclophosphamide and 
mycophenolate Mofetil. Our study included 26 plasma samples and 29 serum samples of 34 
healthy control donors. The IgG production within the brain compartment (intrathecal) was 
calculated as IgG-index ((CSF IgG / CSF albumin) / (serum IgG / serum albumin)). This 
study was approved by the Ethics Committee of the Ludwig Maximilian University of 
Munich. Informed consent was obtained according to the Declaration of Helsinki. 
 
Table 1. Clinical data of patients included in this study  
Age 
(year) 
sex Diagnosis Treatment Related Figure 
52 F RRMS GA + GCS Figure 9 
41 F RRMS GA + GCS Figure 9 
50 M RRMS GCS Figure 9 
40 M RRMS GCS Figure 9 
39 M RRMS AZA + GCS Figure 9 
29 F RRMS GCS Figure 9 
51 F RRMS GCS Figure 9 
29 M RRMS IFN-beta 1a + GCS Figure 9 
32 F CIS GCS Figure 9 
33 F RRMS GA + GCS Figure 9 
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    Figure 9 
50 F RRMS NTZ Figure 9 
33 F RRMS NTZ Figure 9 
34 M RRMS NTZ Figure 9 
28 M RRMS NTZ Figure 9 
50 F RRMS NTZ Figure 9 
56 M RRMS NTZ Figure 9 
37 F RRMS NTZ Figure 9 
38 F RRMS NTZ Figure 9 
31 F RRMS NTZ Figure 9 
56 M RRMS NTZ Figure 9 
     
24 F RRMS no treatment Figure 8 
26 F CIS no treatment Figure 8 
28 M RRMS no treatment Figure 8 
34 F RRMS no treatment Figure 8 
24 F CIS no treatment Figure 8 
43 F CIS no treatment Figure 8 
33 F RRMS no treatment Figure 8 
38 F RRMS no treatment Figure 8 
32 F RRMS no treatment Figure 8 
44 F RRMS no treatment Figure 8 
37 F CIS no treatment Figure 8 
45 F RRMS no treatment Figure 8 
62 F RRMS no treatment Figure 8 
51 M RRMS no treatment Figure 8 
21 F RRMS no treatment Figure 8 
59 F RRMS no treatment Figure 8 
42 F RRMS no treatment Figure 8 
40 F CIS no treatment Figure 8 
21 M CIS no treatment Figure 8 
33 F CIS no treatment Figure 8 
53 M RRMS no treatment Figure 8 
32 M RRMS no treatment Figure 8 
24 F CIS no treatment Figure 8 
37 F RRMS no treatment Figure 8 
38 F RRMS no treatment Figure 8 
45 F RRMS no treatment Figure 8 
24 F RRMS no treatment Figure 8 
27 F RRMS no treatment Figure 8 
22 F RRMS no treatment Figure 8 
26 F RRMS no treatment Figure 8 
62 F SPMS no treatment Figure 8 
46 F SPMS no treatment Figure 8 
59 M SPMS no treatment Figure 8 
62 M SPMS no treatment Figure 8 
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39 M SPMS no treatment Figure 8 
45 F SPMS no treatment Figure 8 
54 F SPMS no treatment Figure 8 
         
46 F Neuroborreliosis no treatment Figure 8 
69 F Neuroborreliosis no treatment Figure 8 
66 M Neuroborreliosis no treatment Figure 8 
55 M Neuroborreliosis no treatment Figure 8 
61 M Neuroborreliosis no treatment Figure 8 
          
45 f SLE no treatment Figure 10 
47 f SLE no treatment Figure 10 
33 f SLE no treatment Figure 10 
27 f SLE no treatment Figure 10 
62 f SLE no treatment Figure 10 
38 f SLE no treatment Figure 10 
40 f SLE no treatment Figure 10 
40 f SLE no treatment Figure 10 
31 f SLE no treatment Figure 10 
39 f SLE no treatment Figure 10 
26 f SLE no treatment Figure 10 
22 f SLE no treatment Figure 10 
20 f SLE no treatment Figure 10 
22 f SLE no treatment Figure 10 
43 f SLE no treatment Figure 10 
55 f SLE no treatment Figure 10 
21 f SLE no treatment Figure 10 
29 f SLE Pred, HCQ Figure 10 
38 f SLE Pred, HCQ, AZA Figure 10 
39 f SLE Pred, HCQ, CYC Figure 10 
54 f SLE Pred, AZA Figure 10 
47 f SLE Pred, HCQ Figure 10 
63 f SLE HCQ, AZA Figure 10 
28 f SLE HCQ Figure 10 
38 f SLE Pred Figure 10 
36 f SLE Pred, MMF Figure 10 
41 f SLE Pred, HCQ Figure 10 
30 f SLE AZA Figure 10 
60 f SLE HCQ, AZA Figure 10 
25 f SLE HCQ Figure 10 
31 f SLE Pred, HCQ, MMF Figure 10 
27 f SLE Pred, CYC Figure 10 
45 f SLE Pred, HCQ, CYC Figure 10 
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22 f SLE Pred, HCQ, CYC Figure 10 
28 f SLE Pred, HCQ, AZA Figure 10 
23 f SLE Pred Figure 10 
25 f SLE Pred, CYC Figure 10 
31 f SLE Pred, AZA Figure 10 
32 f SLE Pred Figure 10 
         
38 F Sensineuronal hearing deficit  Figure 8 
68 F Cerebrovascular disease  Figure 8 
29 M Sensory symptoms  Figure 8 
34 F Sensory symptoms  Figure 8 
45 F Migraine   Figure 8 
26 M Sensory symptoms  Figure 8 
41 F Sensory symptoms  Figure 8 
19 F Vertigo  Figure 8 
31 M Sensory symptoms  Figure 8 
35 F Syringomyelia  Figure 8 
51 M Spinal stenosis   Figure 8 
30 F Neurastenia  Figure 8 
65 M Alcohol-related spastic 
paraparesis 
 Figure 8 
37 F Sensory symptoms  Figure 8 
49 F Hearing deficit  Figure 8 
53 F Depression  Figure 8 
52 F OND  Figure 8 
33 F Fatigue  Figure 8 
40 M Bipolar disorder  Figure 8 
32 M Schizophrenia  Figure 8 
Abbreviations used in this table: GA: Glatiramer Acetate; GCS: Glucocorticosteroid, NTZ: 
Natalizumab, PRED: Prednisolon, HCQ: Hydroxychloroquine, AZA: Azathioprine, MMF: 
Mycophenolate mofetil, CYC: Cyclophosphamide. 
 
3.1.2 Antibodies 
 
Table 2. Primary and secondary antibodies  
Antibody Source Concentration/Dilution 
anti-hBCMA (C12A3.2)  Biogen Idec FC: 1 µg/ml 
WB: 1 µg/ml 
anti-hBCMA (A7D12.2)  Biogen Idec FC: 5 µg/ml 
anti-mBCMA, biotin (BAF593) R&D systems FC: 5 µg/ml 
anti-presenilin (PSEN1) Epitomics WB: 1:2500 
anti-nicastrin (N1660) Sigma-Aldrich WB: 1:5000 
anti-CD40L, FITC (TRAP1) BD PharMingen FC: 1:40 
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anti-CD138, FITC (B-A38) Diaclone FC: 1:10 
anti-CD19, PE (HIB19) BD PharMingen FC: 1:40 
anti-CD19, Cy7 (HIB19) Ebioscience FC: 1:40 
anti-CD27, Cy7 (O323)  Ebioscience FC: 1:20 
anti-CD38, eFluor® 450 (HB7) Ebioscience FC: 1:20 
anti-CD138, PE (281-2) BD Biosciences FC: 1:100 
anti-kappa, Pacific Orange (187.1) DRFZ FC: 1:50 
anti-CD21 (7E9) BioLegend FC: 1:100 
anti-CD23 (B3B4) BioLegend FC: 1:100 
anti-CD24 (clone M1/69) BD Biosciences FC: 1:200 
anti-CD93 (AA4.1) BioLegend FC: 1:50 
anti-CD117 ( 2B8) BD Biosciences FC: 1:200 
anti-IgM (RMM-1) BioLegend FC: 1:20 
anti-B220 (RA3-6B2) DRFZ FC: 1:400 
anti-IgD (11-26c) DRFZ FC: 1:200 
anti-GL-7 (GL-7) DRFZ FC: 1:200 
anti-CD4 (GK1.5) DRFZ FC: 1:200 
anti-CD8 (53-6.7) BioLegend FC: 1:50 
anti-FLAG™ (M2) Sigma-Aldrich FC: 5 µg/ml 
ELISA: 5 µg/ml 
goat-anti-mouse IgG2b, Alexa Fluor® 647 Invitrogen  FC: 1:500 
goat-anti-mouse Ig, PE  Dako FC: 1:50 
goat-anti-mouse IgG, HRP (True blot®) Ebioscience WB: 1:1000 
anti-rabbit IgG, HRP Promega WB: 1:2500-5000 
mouse anti-C99 (4G8) Covance FC: 2 µg/ml 
 
 
3.1.3 Cytokines 
 
Table 3. Cytokines, TLR7/TLR8- agonist  
Protein Description Product number Company 
Recombinant 
Mega APRIL 
H98 
Extracellular domain of mouse 
APRIL (aa 98-232) fused at the 
N-terminus to mouse 
ACRP30headless (aa 18-110) and 
a FLAG®-tag. 
Binds to human and mouse 
BCMA and TACI. Does not bind 
to proteoglycans. 
AG-40B-0035-C010 Adipogen 
Recombinant 
human  
BAFF-FLAG 
Extracellular domain of human 
BAFF (aa 83-285) fused at the N-
terminus to a linker peptide (6 aa) 
and a FLAG®-tag 
ALX-522-025-C010 Enzo Life 
Sciences 
Recombinant  
human BAFF 
 2149-BF-010 R&D 
Recombinant  202-IL R&D 
Materials and Methods 
28 
 
human IL-2 
R848 Resiquimod;  
TLR7/TLR8- agonist 
SML0196-10MG 
 
Sigma Aldrich 
Recombinant  
human IL-21 
 14-8219-62 eBioscience 
 
3.1.4  Protease inhibitors 
 
Table 4. Protease inhibitors  
Target protein Target protease Product number Company 
DAPT γ-secretase 565770 Merck 
Millipore 
LY-411575-I 
(stereoisomer SRR) 
γ-secretase SML0506 Sigma Aldrich 
L-685,458 γ-secretase 2627/1 R&D systems 
RO49290 γ-secretase S1575 Selleckchem 
TAPI-1 MMPs and TACE 579053 Calbiochem 
Merck 
 
3.1.5 ELISA 
 
Table 5. ELISA assays  
ELISA Description Product number Source 
Human BCMA ELISA 
DuoSet 
Sandwich ELISA, 
consisting of 2 polyclonal 
antibodies against human 
BCMA 
DY193 R&D 
Quantokine human 
BAFF ELISA 
Solid Phase Sandwich 
ELISA consisting of a 
monoclonal capture and a 
polyclonal detection against 
human BAFF 
DBLYS0B R&D 
LEGEND MAX™ 
Human 
APRIL/TNFSF13 
ELISA  
Solid Phase Sandwich 
ELISA consisting of a 
monoclonal capture and a 
polyclonal detection against 
human APRIL 
439307 BioLegend 
Human APRIL 
Platinum ELISA 
Sandwich ELISA, 
consisting of 2 polyclonal 
antibodies against human 
APRIL 
BMS2008 eBioscience 
Human IgG ELISA 
assay 
Sandwich ELISA 3850-1AD-6 Mabtech 
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3.1.6 Reagents and buffers  
 
Table 6. Reagents and buffers  
   
PBS  
(phosphate-buffered saline) 
137 mM  
2.7 mM  
10 mM  
2 mM  
 
NaCl  
KCl, 
Na2HPO4 
KH2PO4 
pH 7,4 
Cell isolation buffer 5 g/L 
2 mM 
Bovine Serum Albumin 
EDTA 
RBC lysis buffer 150 mM 
1 mM 
0,1 mM 
NH4Cl  
KHCO3 
Na2EDTA 
NP-40 lysis buffer 150 mM 
50 mM 
1 % 
NaCl,  
Tris pH 7.5  
Nonidet P-40 
BS3 crosslinking conjugation 
buffer 
20 mM 
NaCl 0.5 M 
Sodium phosphate,  
pH 8,6 
BS3 quenching buffer 1 M  Tris HCl  
pH 7.5 
   
   
Silver stain- Fixation buffer 50% Vol. 
12% Vol. 
Methanol 
Acetic acid 
Silver stain- Sensitizing buffer 0.2 g/L  Na2S2O3 
Silver stain- Silver nitrate 
solution 
2 g/L 
0.075% Vol. 
AgNO3 
Formaldehyde 
Silver stain- Developer 60 g/L 
5 mg/L 
0.05% Vol. 
Na2CO3 
Na2S2O3 
Formaldehyde 
Flow cytometry buffer 1% BSA 
0.1 % 
FCS  
Sodium azide 
MES Running buffer (20x) 1 M 
1 M 
2 % (g/V)  
20 mM 
MES 
TRIS-base 
SDS 
EDTA 
H2O, pH 7,3 
Laemmli Loading buffer 3x 
 
 
 
 
 
 
6 % 
30 % 
6 M 
0.006 %  
7.5 % ß-mercaptoethanol 
0.1875 M 
SDS 
Glycerol 
Urea 
bromophenol blue 
 
Tris-Cl 
pH 6,8 
Lower Tris Buffer 1.5 M 
0.4 % 
Tris Base 
SDS 
pH 8.8 
Upper Tris buffer 0.5 M 
0.4 % 
Tris Base 
SDS 
pH 6.8 
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SDS running buffer (10x) 250 mM 
1.92 M 
1% (g/V) 
Tris 
Glycine 
SDS 
Transfer buffer (10x) 250 mM 
2.4 M 
Tris 
Glycine 
I-Blocking buffer  PBS 
0.1 %  
1 g/L 
 
Tween 20 
I-Block™ (Tropix) 
TE Buffer (10x) 108 g/L 
55 g/L 
4.4 % Vol. 
Tris  
Boric acid 
0,5 M EDTA 
pH 8.0, H2O 
 
 
3.1.7 Gels 
 
Table 7. Gels  
Tris-Glycine 
8% polyacrilamide (1 gel) 
4.4 ml 
1.6 ml 
2 ml 
15 µl 
15 µl 
Stacking gel: 
1.7 ml 
0.25 ml 
0.65 ml 
7.5 µl 
7.5 µl 
H2O 
Acrylamide 40 % 
Lower Tris Buffer 
TEMED 
APS 
 
H2O 
Acrylamide 40 % 
Upper Tris Buffer 
TEMED 
APS  
Tris-Glycine 12% Urea (1 gel)  1.1 ml 
2.6 ml 
2.25 ml 
2 ml 
15 µl 
15 µl 
Stacking gel: 
0,45 ml 
1.25 ml 
0.25 ml 
0,65 ml 
7.5 µl 
7.5 µl 
H2O 
Urea 8M 
Acrylamide 40 % 
Lower Tris Buffer 
TEMED 
APS 
 
H2O 
Urea 8M 
Acrylamide 40 % 
Upper Tris Buffer 
TEMED 
APS 
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3.2 Cell culture 
 
3.2.1 General cell culture method 
 
Suspension cell lines, JLK-6 and J558L, were maintained by medium renewal after 3 days. 
Therefore the cell suspensions were centrifuged at 300 g for 5 min and subsequently 
resuspended at a concentration of 1x105 -1x106 cells/ml medium.  
Adherent cell lines, HEK293, HeLa, L-cells were passaged once they reached 80-90% 
confluency by detachment with Trypsin-EDTA (PAA Laboratories, Coelbe, Germany), rescue 
from the protease trypsin with 5 volumes of DMEM media, centrifugation at 1000 rpm for 5 
min at 4°C, and suspension in media for plating. 
BCMA-transfected MEF-cells were detached with EDTA 0,5mM for 2-5 min at 37°C buffer 
to avoid tryptic digestion of BCMA. 
Cell viability was assessed by mixing the cell suspension 1:1 with trypan blue solution (0.4%, 
1:4 in PBS, pH 7.4; Invitrogen) and quantifying on a hemocytometer under the microscope. 
The cells were typically grown in T25, T75, or T175 cell culture flasks (BD Biosciences).  
 
3.2.2 Cell lines 
 
The plasmacytoma suspension cell line JK-6L (Ref. Burger et. al) was cultured in Roswell 
Park Memorial Institute medium (RPMI; Gibco, Darmstadt, Germany) media, supplemented 
with 10% fetal calf serum (FCS; Gibco) and 1% penicillin/streptomycin. After sequential 
adaptation, the plasmacytoma cells were grown in serum-free condition (Hybridoma 6 direkt 
from Bio&SELL, Nürnberg, Germany) with 1% Penicillin/Streptomycin (Invitrogen, 
Darmstadt, Germany). They were incubated in 37°C with 10% CO2.  
HEK293 (human embryonic kidney), and HeLa (human cervical adenocarcinoma) cells were 
cultured in DMEM (Gibco®, Karlsruhe, Germany) supplemented with 10% FCS (Biochrom 
AG, Berlin Germany) and 1% penicillin/streptomycin (Gibco). 
L-cells stably transfected with CD40L were cultured in DMEM supplemented with 10% FCS 
and 4.8 mg/ml Geneticin® G418.  
Mouse embryonic fibroblast (MEF) cells derived from PS1/2-/- mice (kindly provided by Bart 
de Strooper) were cultured in Dulbecco’s modified eagle medium (DMEM, Invitrogen) 
supplemented with 10%FCS and 1% Penicillin/Streptomycin. They were incubated in 37°C 
with 5% CO2.  
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Plasmacytoma mouse cells J558L were cultured in DMEM high Glucose supplemented with 
10% FCS, 1% penicillin/streptomycin (Gibco) and L-glutamine in a final concentration of 
2mM (PAN Biotech, Aidenbach, Germany) and incubated at 37°C with 5% CO2.  
 
3.2.3 Isolation of human peripheral blood mononuclear cells by density gradient 
centrifugation 
 
Blood samples from healthy donors were obtained using the S-Monovette® EDTA K2-Gel 
system. The blood was then diluted 1:1 with PBS, and carefully poured into 50ml falcons 
containing 15ml of Pancoll (human Pancoll, density 1.077 g/l PanBiotech). After 20min 
centrifugation at 2000rpmi (Room temperature, without brakes), the enriched lymphocyte 
fraction was collected and washed twice in PBS (300g, 10min, 4°C) and then resuspended in 
complete RPMI consisting in consisted of RPMI supplemented with 10% fetal calf serum 
(FCS; Gibco), 1% Penicillin/Streptomycin solution (Gibco), and 1% sodium pyruvate 
(Gibco). Approximatively 1-2 106 lymphocytes /ml blood were obtained. Cells were then 
directly stimulated or further isolated as described below. 
 
3.2.4 Human B cell isolation 
 
Human B cells were positively selected from Peripheral blood mononuclear cells (PBMC) 
obtained from healthy donors as described above using CD19 Microbeads (Miltenyi Biotec, 
Bergisch Gladbach, Germany). First PBMC were resuspended in isolation buffer (0.5 % BSA, 
2 mM EDTA, pH 7.2). After determining cell number, the PBMCs were centrifuges (300 g, 
10 min, room temperature) and then resuspended into 80µl buffer /107 cells. 20µl of CD19 
microbeads, magnetic beads labeled with anti-human CD19 antibodies (Miltenyi Biotec) were 
added per 107 cells for 15min at 4°C. Cells were then washed and then resuspended in 500µl 
isolation buffer. The magnetic separation was performed using MS or LS columns and a 
MACS® Separator (Miltenyi Biotec). The appropriate column was placed in the magnetic 
field and the cell suspension was applied to the column. The column was then washed three 
times with the isolation buffer. The column was then removed from the separator and the 
CD19 positive, magnetically labeled cells were then flushed out of the columns by pushing a 
plunger into the column. The collected CD19 positive cells were culture in complete RPMI 
supplemented with 10% FCS, 1% sodium pyruvate and 1% Penicillin/Streptomycin. 
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3.2.5 Human B cell stimulation and differentiation 
 
In order to differentiate human native B cells into Ig-secreting cells, two experimental 
approached were used: 
 
3.2.5.1 CD40L/IL-21 stimulation 
 
CD40L transfected L-cells were suspended in culture medium without genetecin®. The cells 
were then irradiated (7500 rad) and plated in a 96-well flat bottom plate at 5000 cells /well. 
Isolated human B cells (see above) were added to the irradiated CD40L-L cells in a 
concentration of 80,000 cells /well and cultured in RPMI complete for 5 days in the presence 
of IL-21 at a final concentration 50 ng/ml (Ettinger, Sims et al. 2005). 
 
3.2.5.2 Resiquimod/IL-2 stimulation 
 
PBMC were obtained from healthy donors by density gradient centrifugation and resuspended 
in RPMI complete (300,000 cells /ml). Resiquimod at a final concentration of 2.5 µg/ml and 
IL-2 at a final concentration of 1000 UI/ml were added for 7 days (Pinna, Corti et al. 2009). 
 
3.2.6 Mouse B cell isolation and survival assay 
 
Spleens from C57/BL6 mice were homogenized. A single cell suspension was obtained using 
a 100 µM nylon mesh (Merck Millipore). Erythrocyte lysis was done by suspending the cells 
in 2ml RBC lysis buffer for 5 min at room temperature. The splenocytes were then washed 
with PBS, centrifuged (300 g, 10 min, 4°C) and suspended into RPMI complete at a 
concentration of 1x108 cells/ml in a 5 ml polystyrene tube. B cells were magnetically isolated 
(negative selection) using the EasySep™ Mouse B Cell Isolation Kit (Stemcell Technologie, 
Vancouver, Canada) using the protocol from the manufacturer. Normal rat serum (Stemcell) 
and EasySepTM Mouse B cell isolation cocktail (Stemcell) were added. The latter is a 
combination of biotinilated monoclonal antibodies directed against CD4, CD8a, CD11b, 
CD43, CD49b, CD90.2, Ly-6C, TER119 and an FcR blocker. After 10 min incubation at 
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room temperature, streptavidin coated magnetic particles (EasySepTM Streptavidin 
Rapidspheres TM) were added. The magnetic separation was performed using the EasySepTM 
Magnet.  
Flatt bottom, 96-well microtiter plates (Nunc) were precoated overnight at 37°C with anti-
IgM (5 µg/ml) in RPMI. The plates were washed with sterile PBS and the B cells were plated 
at 3x106 cells /well. APRIL-FLAG (100 ng/ml, Adipogen) was added for 48h and cross-
linked with anti-FLAG mAb antibody at a concentration of 1 µg/ml (Sigma-Aldrich). Cells 
were stained for flow cytometry against CD19 and cell survival was quantified by flow 
cytometry using TO-PRO®-3 Iodide viability dye (Invitrogen Life Technologies) and 
APRIL-induced survival was calculated as followed: 100 x [(cell survival in presence of 
APRIL – cell survival without APRIL) / cell survival without APRIL]. 
 
 
3.3 General protein analytics 
 
3.3.1 Cell lysates 
 
Adherent MEF Cells were washed twice with cold PBS. Complete protease inhibitor cocktail 
(Roche Applied Science, Penzberg, Germany) was added to cold NP-40 lysis buffer (150 mM 
NaCl, 50 mM Tris pH 7.5, 1% Nonidet P-40). Cells were suspended by scraping and pipetting 
in the complete NP-40 lysis buffer. After 1h incubation on ice, cell suspensions were 
transferred to precooled aliquots, and centrifuged (20,000 g, 15 min, 4°C). Supernatant were 
collected and stored at -80°C. 
 
3.3.2 Immunoprecipitation 
 
3.3.2.1 Samples 
 
Blood samples from healthy donors were obtained using the S-Monovette® Serum system. 
The tubes were then centrifuged (3000 g, 15 min, RT) and the upper serum fraction was 
collected. Plasmacytoma cells (JLK6) were centrifuged (300 g, 10 min), resuspended in 
serum-free hybridoma media (1,000,000 cells/ml) and cultured for 3 days. Cells were then 
centrifuged and the supernatant was collected. Human B cells were isolated and stimulated 
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with CD40/L and IL21 as described above. After 5 days, the cells were centrifuged and the 
supernatant was collected. To avoid contamination by dead cells and cell debris, all samples 
were centrifuged twice at 300 g (10 min, 4°C) followed by 20,000 g centrifugation (30 min, 
4°C). Supernatant were collected and transferred to a new tube between each centrifugation 
step. Sample were then stored at -20°C. 
 
3.3.2.2 Magnetic beads preparation, antibody coupling and crosslinking 
 
Magnetic beads with recombinant protein G (Dynabeads Protein G, Invitrogen) were used for 
all immunoprecipitation experiments. 35 µg of the monoclonal antibody anti human BCMA 
C12, 35 µg of the monoclonal antibody anti human BCMA A7, and 15 µg of the polyclonal 
antibody anti-human BCMA (R&D), 35 µg of isotype control IgG and 35 µg of isotype 
control IgG2b diluted in 200 µl of PBS-Tween (0,02 %) were incubated with 1.5 mg magnetic 
beads. Magnetic beads were washed twice with PBS-Tween using MagCellet™Magnet 
(R&D). Antibodies couple to the magnetic beads were cross-linked using following protocol: 
Beads were washed twice in crosslinking conjugation buffer. The beads were then incubated 
at room temperature with tilting/rotation twice for 30 min in 250 µl of a freshly prepared 
solution of 5 mM BS3 (bis[sulfosuccinimidyl] suberate). The reaction was quenched by 
adding 12.5 µl of BS3 Quenching for 15 min at room temperature. The beads were washed 3 
times with PBS-Tween (0.02%). 
 
3.3.2.3 Immunoprecipitation 
 
Immunoprecipitation for further Western blot analysis was performed by incubation of 1 ml 
serum, 1 ml plasmacytoma cell supernatant or 5 ml human B cell supernatant with the 
antibody-coupled magnetic beads (overnight with tilting and rotating at 4°C). In order to 
immunoprecipitate a larger amount of sBCMA for latter mass spectrometry analysis, 
successive (10x2ml) incubation of plasmacytoma supernatant were performed using anti-
human BCMA A7 and IgG2b coupled magnetic beads. 
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3.3.2.4 Elution 
 
The magnetic beads-antibody-antigen complex was washed twice with PBS-tween (0.02%) 
and three times with PBS alone. The bead suspension was then transferred to a clean tube 
before the elution. 
For further immunoblotting analysis, denaturing elution was performed by adding 20µl 
premixed NuPage LDS Sample buffer and NuPage Reducing Agent (mixed as per 
manufacturer’s instructions) and heated for 10min at 90°C. The tubes with the beads were 
then placed on the magnet and the supernatant was collected. 
For further mass spectrometry analysis, acidic elution was done by incubating the beads 3 
times with a 1M Glycine solution, pH 3 for 20 min each at 56°C. The eluate was neutralized 
by adding 1M TRIS, pH 9. 
 
3.3.3 Gel electrophoresis, Coomassie staining and Western blot 
 
3.3.3.1 Western blot detection of soluble BCMA upon immunoprecipitation 
 
Samples were separated in 4 - 12 % polyacrylamide gels (Invitrogen, Darmstadt, Germany) 
using the NuPAGE SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) 
system with MES buffer as running buffer. Recombinant human BCMA-Fc was used as a 
positive control. Markers used were the Novex R Sharp Pre-stained protein standard 
(Invitrogen, Darmstadt,Germany) and the Spectra™ Multicolor Low Range protein ladder 
(Thermo Scientific).  
For Coomassie staining, gels were incubated for 20 min in the Coomassie staining solution 
(0.1 % Coomassie Brilliant-Blue, 40 methanol, 10 % acetic acid) under constant shaking at 
room temperature. The background staining was afterwards eliminated by at least three 
subsequent 15 min incubations with the destaining solution (50 % methanol, 7 % acetic acid). 
Gels were eventually stored in 7 % acetic acid.  
For Western blotting, gels were electrically transferred to a polyvinylidene difluoride (PVDF) 
membrane at 50 mA for 80 min using NuPAGE transfer buffer (Invitrogen) by semi-dry 
blotting (Bio-Rad). After blocking in 5 % milk at room temperature for at least 2 h, 
membranes were incubated overnight at 4°C with anti-human BCMA C12 diluted in blocking 
buffer. To avoid interference with residual heavy and light chains resent in the 
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immunoprecipitation eluate, in addition to crosslinking of the ip antibodies, the Mouse 
TrueBlot® ULTRA system was used (1:1000, 2h, room temperature). This HRP-conjugated 
rat-anti-mouse Ig preferentially detects the non-reduced form of mouse IgG.  
 
3.3.3.2 Western blot detection of presenilin 1 and nicastrin 
 
Total protein concentration of cell lysate was quantified using Pierce™ BCA Protein Assay 
kit (Thermo Scientific). 3x Laemmli Loading buffer with ß-mercaptol and 6M Urea was used 
as loading buffer.  
For presenilin and nicastrin immunoblotting, samples were loaded on a 12% Urea Tris-
Glycine gel and on an 8% polyacrylamide Tris-Glycine gel respectively. Samples were 
separated by electrophoresis (80 V, 90 min). Gels were transferred to a PVDF membrane by 
wet electroblotting (400 mA, 65 min, Bio-Rad). PVDF membranes were blocked with 5% 
milk and incubated overnight at 4°C with either a monoclonal rabbit anti-presenilin antibody 
or a polyclonal rabbit anti-Nicastrin antibody. HRP-conjugated goat-anti rabbit Ig was used as 
a secondary antibody. Primary and secondary antibodies for presenilin and nicastrin 
immunoblotting were diluted in PBS-Tween 0.05 %, BSA 0.5 % and in I blocking buffer 
respectively. Detection and imaging was realized with ECL (GE healthcare) using the Gel 
Doc™ system (Bio-Rad). 
 
3.3.4 Mass spectrometric analysis and sample preparation 
 
3.3.4.1 In solution digestion by trypsin followed by mass spectrometry  
 
Immunoprecipitated soluble BCMA from supernatant of plasmacytoma cells obtained by 
acidic elution were desalted and concentrated using C18 StageTips™ (Thermo Scientific) 
following manufacturer’s protocol. Samples were eluted in 80% acetonitrile (ACN) 5% 
formic acid. In-solution tryptic digestion, the LC-MSMS analysis and the subsequent mass 
spectrometric analysis (TQ OrbitrapXL mass spectrometer, Thermo Fischer Scientific) were 
performed by Stephanie Hauck (Research Unit Protein Science, Helmholtz Zentrum 
München). 
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3.3.4.2 Silver staining, in gel digestion by trypsin and chymotrypsin followed by mass 
spectrometry  
 
Immunoprecipitated soluble BCMA from supernatant of plasmacytoma cells were eluted in 
denaturing conditions and loaded on a NuPAGE® Novex® 4-12% Bis-Tris Gel (MES 
running Buffer, 50 V 30min then 100 V 30 min). The gel was fixed with a fixation solution 
twice for 15 min and then washed three times with 50% ethanol. The gel was then sensitized 
with 0.02 % Na2S2O3 for 1-2 min. After the gel was washed with H2O for 5 min, it was 
stained with silver nitrate for 20min. The gel was the washed for 1 min with H2O and 
developed over a period of 5 min. After stopping the staining with 0.5 % glycine for 15 min, 
the obtained band was cut. In gel tryptic and chymotryptic digestion, followed by the LC-
MSMS analysis and the subsequent mass spectrometric analysis (TQ OrbitrapXL mass 
spectrometer, Thermo Fischer Scientific) were performed by Stephanie Hauck (Research Unit 
Protein Science, Helmholtz Zentrum München). 
 
3.4 Molecular cloning 
 
3.4.1 General molecular cloning methods 
 
3.4.1.1 Transformation of bacterial cells 
 
Plasmids were transformed into Escherichia coli (E. coli) cells for amplification. Typically, 
10 ng of plasmid preparation or 1 μL of ligation reaction was added into 50 μL of electro-
competent DH5-cells. After incubation on ice for 30 min, the cells were heated-shocked at 42 
°C for 90 sec in a thermomixer, and then returned to ice. For recovery, 450 μL of LB-media 
was added and then the cells were placed in a 37 °C shaker at 150 rpm for 30 min. 
Afterwards, the cells were plated on LB- agar plates supplemented with the appropriate 
selection antibiotic and incubated at 37°C.  
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3.4.1.2 Plasmid purification from bacterial cells 
 
Bacterial colonies of interest were picked and inoculated to LB-media supplemented with the 
appropriation selection antibiotic. Plasmid DNA was purified from E. coli cells by using 
miniprep and maxiprep kits (Qiagen, Hilden, Germany), following protocol from the 
manufacturer. The resulting plasmid DNA was used for sequence verification, further cloning 
procedures, or cell transfection. 
 
3.4.1.3 Agarose gel electrophoresis  
 
To cast an agarose gel, agarose powder was dissolved in TBE buffer by heating and poured 
into a self-assembled mold with an appropriate comb. The percentage of agarose varied from 
1-1.5% depending on the interested DNA size. SYBR@Safe DNA Gel Stain (1:10,000, 
Invitrogen) was added into the gel mixture at to visualize DNA under UV light. The gel was 
then placed in TBE buffer in a horizontal electrophoresis chamber. Samples were mixed with 
6x gel loading dye (Thermo scientific) and loaded into the wells. DNA ladders (100 bp or 1 
kb; New England Biolabs) were included for size recognition. The electrophoresis conditions 
were 100 mV for 30 min to 1 h at room temperature. Afterwards, the gels were visualized in a 
UV light box. 
 
3.4.1.4 DNA extraction from agarose gel 
 
DNA molecules were eluted from agarose gel pieces cut from the whole gel with a scalpel in 
the UV light box. The elution was done using QIAquick Gel Extraction Kit following 
manufacturer’s protocol. 
 
3.4.1.5 Cloning primers 
 
Table 8. Cloning primers  
Name Description Sequence 5’-3’ 
BCMA-
SgfI-fw 
SgfI restriction 
site 
GAGGCGATCGCCATGTTGCAGAT 
BCMA-
MluI-rev 
MluI restriction 
site 
GCGACGCGTTTACCTAGCAGAAATTGATT 
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BCMA-
EcoRI-fw 
EcoRI 
restriction site 
GATCGAATTCCGGATGTTGCAGATGGCTGG 
BCMA-
NotI-rv 
NotI restriction 
site 
GATCGCGGCCGCATTCTTACCTAGCAGAAATTGATTTCTC 
BCMA-
EcoRI-fw 
EcoRI 
restriction site 
ATCCGGAATTCATGTTGCAGATGGCTGGGC 
BCMA-
SgfI-Rv 
SgfI restriction 
site 
GCGGCGATCGCTCCTTTCACTGAATTGGTCACACTTG 
 
3.4.1.6 Plasmids 
 
Table 9. Plasmids  
Name Backbone description 
BCMA WT pCMV-XL5 Human BCMA  
pCMV6-AN-DDK pCMV6 Destination vector,  
DDK tag N-terminal 
pcDNA3.1 Zeo(+) pcDNA3.1  
psPAX2 psPAX2  
pCDNA3.1 (-)-VSV-G pCDNA3.1 (-)  
pCR8GWTOPO pCR8/GW/TOPO Entry vector 
pLV FU-ΔZeo  Destination vector 
peak12-SP-C99 pEAK Expresses the C-terminal 99 
amino acids of APP together with 
the APP signal peptide 
 
 
3.4.1.7 Polymerase chain reaction  
 
PCR was performed using a thermocycler (Biometra, Goettingen, Germany). All primers 
were designed to have an annealing temperature between 58-64 °C and were synthesized by 
Metabion (Martinsried, Germany). A typical amplification reaction involved a sample of 
template DNA (ex. cDNA, PCR product, plasmid, bacteria cells), two oligonucleotide 
primers, deoxynucleotide triphosphates (dNTPs), reaction buffer, magnesium, and a 
thermostable DNA polymerase. Taq DNA polymerase (Roche, Penzberg, Germany) was used 
unless otherwise specified. The reaction involved an initial denaturing step at 95 °C for 3 min. 
This was followed by typically 25-30cycles consisting of: (1) Denaturation step at 95 °C for 
30sec, (2) Annealing step at between 55-60 °C for 30 sec, and (3) Elongation step at 72 °C. 
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The elongation time of the final cycle was set to 10 min to ensure that all products were fully 
extended. The PCR product was stored at 4°C. 
 
3.4.1.8 DNA digestion with restriction endonuclease 
 
Restriction digestion using endonucleases was performed on PCR products and plasmids 
using conventional restriction. For each enzyme, the digest reaction was carried out according 
to the manufacturer’s recommendation of buffer usage and temperature for incubation. 
Double digest reactions were carried out if a compatible buffer existed and if the two 
recognition sequences were sufficiently far apart from each other to avoid steric hindrance.  
 
Table 10. Restriction enzymes  
Enzyme Restriction site 5’-3’ Manufacturer 
SgfI GCGAT*CGC Promega 
MluI A*CGCGT New England BioLabs 
EcoRI-HF G*AATC New England BioLabs 
NotI-HF GC*GGCCGC New England BioLabs 
 
3.4.1.9 DNA ligation 
 
DNA fragments generated by PCR or by restriction were ligated to the vector to produce a 
plasmid. After determining the DNA concentration of each fragment or the linearized vector, 
a ratio of 1 (vector) to 4 (insert) was used to form a complete plasmid. T4 DNA ligase 
(Invitrogen) was used here and reactions were set up according to the protocol provided by 
the manufacturer, and incubated at room temperature for 60 min or at 16 °C overnight. After 
the ligation reaction, 10 μL of the ligation product was used to transform E. coli cells (Section 
3.1.2.1), typically DH5α. 
 
3.4.1.10 DNA quantification 
 
DNA concentration was measured on a Nanodrop spectrophotometer (Peqlab, Erlangen, 
Germany). After a blank measurement was done with the DNA buffer, 2 μL of DNA sample 
was loaded onto the stage for photometric measurement at 260 nm, and the concentration and 
purity of the DNA sample were measured. 
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3.4.1.11 Transfection protocol 
 
HEK293T oder Hela cells were plated to be 70-90% confluent after 24h. Lipofectamin 2000 
(Invitrogen) was diluted in Opti-MEM™ (Invitrogen) medium (1:20-1:100, 5 min, RT). DNA 
(0,5 µg-10 µg) was diluted in the same volume of Opti-MEM™. The diluted DNA was then 
added to the lipofectamin 2000 and the mixture was incubated for 20 min at RT. The DNA 
lipofectamin mixture was then added directly to the cells. 
 
3.4.2 Soluble BCMA generation 
 
To produce soluble BCMA and soluble BCMA with N-terminal-FLAG tag, HEK293 cells 
were transfected within 10 cm cell culture dishes with expression plasmids of full-length 
human BCMA and full-length human BCMA with an N-terminal-FLAG (BCMA-FLAG) 
using lipofectamine 2000 (Invitrogen Life Technologies), as described above. Supernatant 
was harvest after 48h. Control supernatant was produced by parallel transfection of HEK293 
cells with the corresponding empty vector. sBCMA concentrations were determined by 
ELISA. 
 
3.4.3  NF-κB assay 
 
To measure NF-κB activation, HEK293T cells were transiently transfected with a plasmid 
containing a firefly luciferase reporter gene under the control of an NF-κB transcriptional 
response element, a plasmid with a Renilla reniformis luciferase reporter gene for 
normalization and the indicated amounts of expression or control plasmids using 
Lipofectamine 2000 (Invitrogen Life Technologies). To determine the effect of γ-secretase 
inhibition on NF-κB activation, BCMA-transfected cells were treated with DAPT or a solvent 
control and 6 hours later stimulated with APRIL-FLAG or BAFF. To analyze a possible 
decoy function, DAPT along with BAFF or APRIL-FLAG were added to BCMA-Fc or 
supernatants generated by HEK293T cells that had been transfected with full-length BCMA 
or an empty control vector as described above. These supernatants were incubated at 37°C for 
30 minutes and then added to BCMA or TACI-transfected and DAPT-treated cells used for 
the reporter assay. 16 hours after stimulation cells were harvested and cell lysates were 
prepared using passive lysis buffer (Promega) and the reporter gene activity was measured 
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using firefly luciferase substrate (Biozym) and renilla luciferase substrate (Promega) 
respectively (cooperation with Franziska Hoffmann).  
 
3.4.4  Wild-type human BCMA, N-terminal-FLAG-BCMA and extended hBCMA-
BCMA 
 
A human BCMA cDNA clone (SC125656) was purchased from Origene. The plasmid DNA 
was sequenced following the manufacterer’s protocol and using the provided sequencing 
primers. To obtain BCMA with an N-terminal FLAG-tag, full-length human BCMA (h184) 
from a human BCMA cDNA clone (OriGene Technologies) was first amplified by PCR. 
Primers were designed to append SgfI and MluI cloning sites at the 5’ and 3’ respectively end 
of the BCMA sequence. The restriction of the obtained PCR fragment and the digestion of the 
destination vector pCMV6-AN-DDK were performed by conventional double digestion with 
SgfI and MluI (NEB buffer 3). Both restriction products were loaded on an agarose gel. The 
bands of interests were cut and eluted using (QIAquick Gel extraction Kit). Ligation was 
performed using a 1 (PCR fragment) to 4 (vector) ratio as described above. 10µl of the 
ligation product was used to transformed DH5α E. coli cells. Afterwards, the cells were plated 
on LB- agar plates supplemented with Ampicillin and incubated at 37°C. Colonies of interest 
were picked and inoculated to LB-media with Ampicillin. Bacterial DNA was extracted as 
described previously. Control digestion using SgfI and MluI as well as vector sequencing 
using the provided sequencing primers was done.  
To obtain a BCMA variant with a prolonged extracellular part, the extracellular part of 
hBCMA was amplified by PCR using human BCMA cDNA clone (SC125656) as a template 
and primers designed to append EcoRI and SgfI cleavage sites at the 5’ and 3’ site 
respectively of the extracellular domain. The obtained PCR product and the N-terminal-
FLAG-BCMA plasmid (see above) were digested using conventional double digestion by 
EcoRI and SgfI. The ligation resulted in a human BCMA construct that contains a full length 
human BCMA and an additional extracellular domain. The original N-terminal Flag is 
removed during the process. 
The plasmid peak12-SP-C99 expresses the C-terminal 99 amino acids of APP together with 
the APP signal peptide. C99 is a direct substrate for γ-secretase. Peak12-SP-C99 was obtained 
by cloning SP-C99 from the pCEP4 vector into the peak12 plasmid (Mitterreiter, Page et al. 
2010).  
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3.4.5 BCMA transduction and rescue of MEF PS-/- deficient cells 
 
3.4.5.1 Generation of hBCMA expressing ® Gateway lentiviral plasmid 
 
Full-length human BCMA (h184) from a human BCMA cDNA clone (OriGene 
Technologies) was first amplified by PCR. Primers were designed to append EcoRI and NotI 
cloning sites at the 5’ and 3’ respectively end of the BCMA sequence. The restriction of the 
obtained PCR product and the digestion of the vector pcDNA3.1/Zeo(+) were performed by 
conventional double digestion with EcoRI-HF and NotI-HF (NEB buffer 4). After gel 
purification of the restriction products, ligation was performed as described above. The 
BCMA insert was released from the obtained vector pcDNA3.1/Zeo(+)-hBCMA by double 
digestion with BamH1 and NotI (NEB buffer 3) and subcloned into the GATEWAY® entry 
vector pCR8GWTOPO, resulting in a plasmid containing the human BCMA gene with 2 
flanking recombination sequences called “att L 1” and “att L 2”. The transfer of BCMA or LR 
reaction into the destination lentiviral vector pLV FU-ΔZeo (containing the “att R” 
recombination sites) was performed following the manufacture’s protocol (Invitrogen, Life 
technologies, Carlsbad CA). To summarize, the LR recombination reaction was performed 
with a 1:1 ratio (entry vector: destination vector). And TE buffer was added to reach an end 
volume of 8µl. LR Clonase™II was added. After 1 hour incubation, the reaction was 
terminated using 1µl Proteinase K (collaboration with Peer-Hendrik Kuhn, Neuroproteomics, 
Klinikum rechts der Isar, Technische Universität München, Munich). 
 
3.4.5.2 Generation of a stable BCMA-expressing MEF PS (-/-) cell line 
 
Lentiviruses were generated by transient cotransfection of HEK293T cells with the plasmids 
psPAX2, pCDNA3.1 (-)-VSV-G as previously described (Kuhn et al. 2010). For generation of 
MEF PS1/2 (-/-) cells stable expressing BCMA, transfer vectors FKP-5XUAS-BCMA and 
FUΔZeo-Gal4-VP16 were separately packed into lentiviral particles. For the rescue of 
Presenilin-1 expression in MEF PS1/2 (-/-) cells, lentiviral particles were generated with the 
transfer vector FU-Valentin-PS1wt or as a control the catalytically inactive Presenilin-1 
mutant D385. For transduction, medium was replaced by fresh antibiotic-free DMEM High 
Glucose supplemented with Pyruvate and 10% fetal calf serum medium 1 day after 
transfection. Overnight conditioned medium containing both FUΔZeo-Gal4-VP16 and FKP-
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5XUAS-BCMA lentiviral particles was filtered through 0.45 µm sterile filters and directly 
added to MEF PS1/2 (-/-) cells. After 6 h, medium was exchanged against cell type-specific 
growth medium of the target cells. After determining the adequate concentration of the 
selection antibiotic by performing a killing curve with different puromycine concentrations, 
BCMA expressing MEF PS (-/-) cells were cultured in the presence of 2µg/ml puromycine to 
eliminate non-transduced cells. Afterwards, Presenilin expression was rescued with FU-
Valentin-PS1 wt particles or FU-Valentin-PS1-D385A particles as a control. 
MEF PS(-/-) cells, MEF PS(-/-) BCMA, MEF PS(-/-) BCMA-D385A and MEF PS(-/-) 
BCMA-PS1 were plated in a 6-well plate (250,000cells/well). After 24h, BCMA surface 
expression was measured by flow cytometry as described in section 3.6. Supernatant was 
collected to measure sBCMA levels. Detection of Nicastrin, Presenilin and BCMA on cell 
lysate was performed by immunoblotting as described earlier (collaboration with Peer-
Hendrik Kuhn, Neuroproteomics, Klinikum rechts der Isar, Technische Universität München, 
Munich). 
 
3.5 Enzyme-linked immunosorbent assay (ELISA) 
 
Soluble BCMA was detected in serum, plasma, CSF and cell culture supernatant using a 
commercially available human BCMA ELISA kit (R&D, DY193), following manufacturer’s 
instructions. To avoid contamination with dead cells or cell debris, samples were sequentially 
centrifuged, 2x 10 min at 300 g, 4 °C and 30 min at 20,000 g, 4 °C. Between each 
centrifugation step, supernatants were transferred to a clean tube. Samples were incubated 
overnight at 4 °C. Absorption was measured with a Wallac Victor2 1420 multilabel counter 
(PerkinElmer) at 450 nm. 
Soluble BAFF was measured using precoated ELISA plate (DBLYS0B, R&D). Samples were 
prepared and incubate as described above.  
To quantify human IgG levels in cell culture supernatants, ELISA assay for human IgG 
(Mabtech) was used. Absorption was measured with a Wallac Victor2 1420 multilabel 
counter (PerkinElmer) at 405. Day-to day controls were used to allow comparison within 
value of different ELISA plates. 
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3.6 Flow cytometry 
 
Cells were transferred into 96-well V-bottom plates (Nunc), centrifuged at 300 g for 5 min at 
4°C and washed twice with 200 μl flow cytometry buffer (Table 6). Cell pellet was 
resuspended in 50 μl/well flow cytometry buffer containing directly labeled antibodies (Table 
2) and incubated for 30 min at 4°C in the dark. Cells were washed three times and 
resuspended in 200 μl flow cytometry buffer.  
Human BCMA cell surface expression was measured by staining with anti-human BCMA 
C12 at 5µg/ml. RPE-conjugated goat anti-human IgG was used as a secondary antibody. 
Mouse BCMA expression was detected by staining with a biotin-conjugated goat anti-mouse 
BCMA polyclonal antibody followed by staining with RPE-conjugated streptavidin. 
For multi-staining of BCMA with CD19, CD27 and CD38, anti-human BCMA A7 was used 
followed by staining with mouse anti-IgG2b-647 secondary antibody.  
APRIL-binding to human plasmacytoma cells was detected as followed. After overnight 
treatment with or without DAPT, cells were washed and incubated for 4 hours (37°C) with 
APRIL-FLAG. The cells were then washed with FACS buffer and stained with anti-FLAG 
M2 antibody (Sigma-Aldrich). RPE-conjugated goat anti-human IgG was used as a secondary 
antibody. Fluorescence was measured using a FACSverse™ flow cytometer (BD) and data 
were analyzed with FlowJo 7.6 software (TreeStar, Ashland, USA).Cell survival was 
quantified by flow cytometry using TO-PRO®-3 Iodide viability dye (1:4000, Invitrogen) 
In mice, single cell suspensions were prepared from bone marrow and spleen. The detection 
of plasma cells was carried out with anti-CD138-PE (clone 281-2; BD Biosciences) for 
surface staining and anti-kappa Pacific Orange (clone 187.1; DRFZ) for intracellular staining. 
B and T cells were identified with following anti-mouse antibodies: CD21 (clone 7E9, 
BioLegend), CD23 (clone B3B4, BioLegend), CD24 (clone M1/69, BD Biosciences), CD93 
(clone AA4.1, BioLegend, CA, USA), CD95 (clone Jo2, BD Biosciences), CD117 (clone 
2B8, BD Biosciences), IgM (clone RMM-1, BioLegend), B220 (clone RA3-6B2, DRFZ), IgD 
(clone 11-26c, DRFZ), GL-7 (clone GL-7, DRFZ), CD4 (clone GK1.5, DRFZ) and CD8 
(clone 53-6.7, BioLegend). Identification of B cell subsets in the spleen: B1: IgMhighCD21low/-
CD23-CD93-. Follicular B cells: IgM+CD21+CD23+CD93-.Marginal zone B cells: 
IgMhighCD21+CD23-CD93-. GL-7+: GL-7+IgD-. Identification of B cell subsets in the bone 
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marrow: pro-B cells: B220+CD93+CD117+. pre-B cells: B220+CD24+IgM-IgD-. Immature B 
cells: B220+CD24+IgM+IgD-. Mature B cells: B220+CD24low/-IgM+IgD+. Cytometric analysis 
was performed using a FACSCanto II cytometer (BD Biosciences) and data were analysed 
with FlowJo software (Tree Star Inc.). Source and working concentration of antibodies used 
are listed in Table 6. Flow cytometric analyses in animal experiments were performed by our 
collaborators (see below).  
 
3.7 Immunization and γ-secretase inhibitor treatment in vivo.  
 
Two different mouse models were applied. First, two months old C57/BL6 mice were 
immunized intraperitoneally with 100 µg OVA and 10 µg LPS in alum (Pasare and 
Medzhitov 2005) and sacrificed 10 days later. Immunized mice received an intraperitoneal 
dose (10 mg/kg) of LY-411575-I on day 9, followed by another dose 6 hours before sacrifice. 
These animal experiments were performed in collaboration with Dr. Yuan-Yuan Chu and 
Prof. Dr. Marc Schmidt-Supprian at the Department of Internal Medicine III, Klinikum 
Rechts der Isar, Technische Universität München, Munich. 
Second, female 16-18 weeks NZB/W F1 mice were bred at the animal facility of the German 
Rheumatism Research Center Berlin (DRFZ) under defined, pathogen-free conditions. To 
distinguish between short-lived and long-lived plasma cells, we fed the mice 
bromodeoxyuridine (BrdU, Sigma-Aldrich, 1mg/ml) with 1 % glucose in drinking water for 
two weeks. One week after start of BrdU feeding, mice were treated daily with the γ-secretase 
inhibitor LY-411575-I intraperitoneally at a dose of 10 mg/kg for 7 days. These animal 
experiments were performed in collaboration with Dr. Qingyu Cheng and Prof. Dr. Falk 
Hiepe at the Deutsches Rheuma-Forschungszentrum in Berlin. 
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4 RESULTS  
 
4.1 Contribution statement 
 
NF-κB assays were performed in collaboration with Dr. Franziska Hoffmann (Institute of 
Clinical Neuroimmunology, LMU Munich). 
BCMA transduction and rescue of MEF PS-/- deficient cells were performed in collaboration 
with Dr. Peer-Hendrik Kuhn (Neuroproteomics, Klinikum rechts der Isar, Technische 
Universität München, Munich). 
Immunization of C57/BL6 mice, treatment with γ-secretase inhibitor and flow cytometric 
analysis of bone marrow cells were performed by Dr. Yuan-Yuan Chu and Prof. Dr. Marc 
Schmidt-Supprian (Department of Internal Medicine III, Klinikum Rechts der Isar, 
Technische Universität München, Munich).  
γ-secretase treatment of NZB/W mice and flow cytometric analysis were performed by Dr. 
Qingyu Cheng and Prof. Dr. Falk Hiepe at the Deutsches Rheuma-Forschungszentrum in 
Berlin. 
Mass spectrometric analyses were performed by Dr. Stephanie Hauck (Research Unit 
Protein Science, Helmholtz Zentrum München). 
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4.2 Detection of soluble BCMA  
 
4.2.1 sBCMA in healthy subjects and patients with neuroinflammatory diseases 
 
We first addressed the question whether soluble forms of BCMA could be detected in serum 
and plasma samples of healthy controls and patients with neuroinflammatory diseases.  
Indeed, sBCMA was regularly detected by ELISA in the plasma of each of 83 analyzed 
donors. sBCMA levels were similar in healthy controls (mean=17.95 ng/ml), in patients with 
CIS or MS (mean=20.93 ng/ml) and in patients with other neurological diseases (mean=20.30 
ng/ml) (Figure 8A). We compared sBCMA levels in 14 matched serum/plasma pairs and 
found that the levels in serum and plasma were very similar (difference for each pair less 
<10%, Figure 8B). Moreover, sBCMA was detected in the cerebrospinal fluid (CSF) of 
patients with other non-inflammatory neurological diseases (OND, mean= 0.091 ng/ml) and 
at enhanced levels in the CSF samples of patients with CIS and MS (mean= 0.348 ng/ml, p< 
0.001), and neuroborreliosis (mean= 0.754 ng/ml, p< 0.001, Kruskal-Wallis test followed by 
Dunn’s Multiple Comparison Test) (Figure 8C). We did not observe significant differences 
between the sBCMA levels in the different clinical forms of multiple sclerosis (Figure 8D; 
clinical isolated syndrome, CIS, mean= 0.277 ng/ml; relapsing remitting multiple sclerosis, 
RRMS, mean=0.370 ng/ml; Secondary progressive MS, SPMS, mean= 0.386 ng/ml).  
A hallmark of MS is the persisting Ig production, which is regularly quantified in the 
neurological clinical routine by the IgG-index, calculated as follows, IgG-Index = (CSF IgG / 
CSF albumin) / (Serum IgG / serum albumin)). We found a strong correlation between 
sBCMA levels in the CSF and the intrathecal IgG production (Figure 8E). This correlation 
was evident when all CSF samples were considered (p <0.0001, r= 0.85, Spearman rank 
correlation) and also within the MS group (p< 0.0001, r= 0.77, Spearman rank correlation).  
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Figure 8. sBCMA is elevated in the spinal fluid of patients with neuroinflammatory 
diseases and correlates to local IgG production. (A) sBCMA plasma concentrations were 
determined by ELISA in healthy controls (grey symbols, HC), CIS/MS (red symbols) and 
OND patients (blue symbols). (B) sBCMA levels were measured by ELISA in plasma/serum 
pairs of 14 healthy controls. Bars represent means. (C) sBCMA in the CSF was determined by 
ELISA in patients with a clinically isolated syndrome (CIS) or multiple sclerosis (MS), 
neuroborreliosis (black symbols, NB), and other neurological diseases (OND) (p<0.001, 
Kruskal-Wallis test followed by Dunn’s Multiple Comparison Test). (D) sBCMA levels in 
different subset of multiple sclerosis (measured in a) were determined. (E) sBCMA in the CSF 
correlated strongly with the intrathecal IgG production represented by the IgG-Index. This 
correlation was evident when all analyzed CSF samples were considered (p <0.0001, r= 
0.85) and also within the MS/CIS group (p< 0.0001, r= 0.77, Spearman rank correlation). 
Modified from Laurent, Hoffmann et al. 2015. 
 
4.2.2 Effects of immunosuppressive treatments on sBCMA levels in patients with 
multiple sclerosis  
 
We aimed to examine whether immunosuppressive treatments in MS such as steroids or 
natalizumab would lead to alterations of the levels of sBCMA. 
Natalizumab, a blocking antibody to α4-integrin, which prevents the entry of lymphocytes 
into the CNS and the IgG production (Ransohoff and Engelhardt 2012), reduces relapses in 
MS patients and is given as a monthly infusion. To further investigate the effect of 
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natalizumab on sBCMA levels, we analyzed longitudinally the CSF of 25 patients before 
initiation of natalizumab treatment and 12 months after continuous treatment. This treatment 
reduced the level of sBCMA in 24/25 patients in the CSF after 12 months (mean=1.10 ng/ml 
before, and mean=0.686 ng/ml after natalizumab treatment; p<0.0001, Wilcoxon matched-
pairs ranked-test), the strongest decrease of sBCMA was observed in those MS patients with a 
particularly high level of sBCMA (Figure 9A).  
We have analyzed longitudinally 10 MS patients, who received high-dose (1000 mg/d) 
methylprednisone (Urbason®) IV over 3 to 5 days, a common treatment of relapses in MS. 
Serum samples were obtained before the first steroid application, on the 3rd day before the 3rd 
infusion and 4 weeks later. We noted a significant decline of sBCMA 3 days after begin of 
methylprednisone treatment (mean= 24,55 ng/ml at baseline; mean=18.58 ng/ml at 3 days, p< 
0.05, Friedman test), while four weeks later an increase of the sBCMA levels compared to the 
3 days after treatment was observed (mean=21.70 ng/ml). (Figure 9B) 
 
 
Figure 9. sBCMA levels under immunosuppressive treatments in blood and CSF. (A) 
sBCMA in the CSF of 25 MS patients (other patients than those in Figure 1) were determined 
before and 12 months after natalizumab treatment. Natalizumab treatment reduced sBCMA 
levels in the CSF in 24/25 patients (p<0.0001, Wilcoxon matched-pairs ranked-test). (B) 
sBCMA levels in the serum of 10 MS patients were determined before, 3 days and 4 weeks 
after the beginning of high dose glucocorticoid treatment, which reduced sBCMA levels 
within 3 days (p<0.05, Friedman test). Modified from Laurent, Hoffmann et al. 2015. 
. 
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4.2.3 sBCMA in patients with systemic lupus erythematosus  
 
Since the BAFF/APRIL pathway plays an important role in the pathogeny of SLE, we went 
on analyzing the presence of sBCMA in SLE patients. We found that in these patients, serum 
levels of sBCMA and BAFF were elevated as seen in an untreated and in a treated cohort 
(Figure 10A, 10B). APRIL levels in healthy controls (mean= 62.7 ng/ml) were found 
elevated when compared to the treated SLE patients (mean= 43.2 ng/ml, p= 0.0033, Kruskal-
Wallis test followed by Dunn’s Multiple Comparison Test), and when compared to all SLE 
patients. Immunosuppressive treatment of SLE patients reduced sBCMA levels (Figure 10A). 
We noted a strong correlation of serum sBCMA and disease activity as measured by the SLE 
disease activity index (SLEDAI), which reflects the severity of systemic organ involvement 
(Figure 10D). We observed an inverse correlation with the paraclinical marker complement 
factor 3 (Figure 10E). There was a trend (p= 0.0767, r= 0.23, spearman correlation) for 
correlation between anti-dsDNA titer and sBCMA in these SLE patients. Serum BAFF levels 
were elevated in our SLE cohort (Figure 10B; mean= 0.61 ng/ml in healthy controls; mean= 
2.11 ng/ml in SLE patients, p= 0.0004, Kruskal-Wallis test followed by Dunn’s Multiple 
Comparison Test), and correlated with sBCMA levels (p= 0.0013, r= 0.47, spearman 
correlation).  
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Figure 10. sBCMA is elevated in the serum of patients with systemic lupus erythematosus 
and correlates to paraclinical and clinical disease activity. (A) sBCMA determined by ELISA 
is elevated in treated and untreated patients with SLE in comparison to healthy controls (HC) 
(***, p<0.001 and *, p<0.05, Kruskal-Wallis test followed by Dunn’s Multiple Comparison 
Test). (B) BAFF levels in the serum was determined by ELISA and was found elevated in 
untreated SLE patients (***, p<0.001 Kruskal-Wallis test followed by Dunn’s Multiple 
Comparison Test) (C) APRIL levels in the serum was determined by ELISA (**, p<0.001 
Kruskal-Wallis test followed by Dunn’s Multiple Comparison Test) and was found reduced in 
the serum of SLE patients (D) sBCMA in serum of SLE patients correlated strongly with 
disease activity quantified with SLE disease activity index (SLEDAI) (p<0.001; r= 0.54, 
Spearman correlation). (E) sBCMA in serum of SLE patients inversely correlated with the 
level of the complement factor C3 (p<0.0374, r= -0.29, Spearman correlation). Bars 
represent means. Modified from Laurent, Hoffmann et al. 2015. 
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4.2.4 sBCMA is released by human B cells upon differentiation into Ig-secreting cells 
 
Previous studies have determined that BCMA upregulation is a consequence of B cell 
differentiation into Ig-secreting cells (ISC) (Darce, Arendt et al. 2007). To assess whether this 
was also applicable for sBCMA production we applied two different protocols. On one hand, 
human B cell were isolated from blood of healthy donors and differentiated in a T-cell 
dependent manner, into ISCs trough stimulation over 5 days with CD40L and IL-21. 
Alternatively, total peripheral blood mononuclear cells were obtained from healthy donors 
and activated by stimulation with the TRL7/8 agonist resiquimod (R848) and IL-2 as 
represented below (Figure 11).  
 
Figure 11. In vitro differentiation of native B cells into Ig-secreting cells with either 
CD40/IL-21 or Resiquimod (R848)/IL-2 stimulation. PBMC contain native B cells 
 
While human B cells activated via CD40L alone released low, but detectable levels of 
sBCMA, this was strongly enhanced by addition of IL-21 (Figure 12A). After, stimulation of 
PBMCs with R848/IL-2 for 7 days (Figure 12B), release of sBCMA was observed as well. 
The appearance of sBCMA was concomitant to the occurrence of Ig-secreting cells. Upon 
activation with CD40L+IL-21, we could distinguish two cell B cell populations, CD19+CD38- 
and CD19+CD38+ cells (Figure 12C). While mBCMA was absent on unstimulated B cells, 
we saw a low mBCMA expression on CD19+CD38- cells and a strong mBCMA expression on 
CD19+CD38+ cells (Figure 12D). After sorting CD38+ and CD38- cells and culturing them 
for another 24 h without further stimulation, we determined the amount of shed BCMA 
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(Figure 12E). This revealed a close correlation between released sBCMA and surface 
expression of mBCMA (Figure 12F). 
 
  
Figure 12. sBCMA is released when B cells differentiate towards plasma cells. (A) Human 
purified B cells were activated for 5 days as indicated; IgG and sBCMA in the supernatant 
were quantified by ELISA. Combined data of 3 independent experiments (mean±SEM, 
p=0.0073, paired t-test). (B) PBMC were stimulated with R848+IL-2 for 7 days. IgG and 
sBCMA in the supernatant were quantified by ELISA. Combined data of 3 independent 
experiments (mean±SEM, p= 0.0227, paired t-test). (C-E) Human purified B cells were 
stimulated with CD40L + IL-21. (C) After CD40L/IL-21 stimulation 2 cell populations 
CD19+CD38- and CD19+CD38+ could be distinguish. (D) Surface BCMA was measured by 
flow cytometry on unstimulated B cells, CD19+CD38- cells and CD19+CD38+ cells. (E) 
Sorted CD38+ and CD38- cells, were cultured for another 24 h and the amount of shed 
sBCMA was measured by ELISA, combined data of 2 independent experiments. (F) 
Correlation between sBCMA release and surface expression of BCMA for a single replicate. 
Modified from Laurent, Hoffmann et al. 2015. 
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4.3 Characterization of sBCMA 
 
4.3.1 Immunoprecipitation of sBCMA and Western blot analysis 
 
We set out to investigate the biological biochemical features and mechanisms underlying the 
release of sBCMA. We found that BCMA and the plasma cell marker CD138 were uniformly 
expressed by the cell line JKL-6 (Figure 13). Moreover sBCMA was detected by ELISA in 
the supernatant.  
 
Figure 13. BCMA and CD138 expression in human plasmacytoma cells. BCMA and CD138 
expression was measured by flow cytometry in JKL-6 cells (closed histogram: isotype control; 
open histogram: BCMA staining). 
 
 
In order to gain further insights into the biochemical features of sBCMA we 
immunoprecipitated sBCMA from supernatant of the plasmacytoma cell line JKL-6 using 
either anti-hBCMA mAb A7D12.2 or C12A3.2. (Figure 14A, B). 
Immunoprecipitation of sBCMA from serum and supernatant of native B cells cultured with 
CD40L and IL-21 was performed using respectively either a goat anti-hBCMA polyclonal Ab 
or the mAb A7D12.2. (Figure 14A). These antibodies were coupled to Dynabeads® Protein 
G and cross-linked with bis-sulfosuccinimidyl-suberate (BS3). Before immunoprecipitation 
supernatants and serum samples were centrifuged twice at 500 g for 10 minutes and once at 
20.000 g for 30 minutes to avoid sample contamination with cell debris. After successive 
incubation with either supernatant of plasmacytoma cells or serum, we eluted with glycine or 
SDS loading buffer, and then performed SDS gel separation. BCMA was then detected either 
by Western blot (Figure 14A) using the mAb C12A3.2 which is directed against the 
extracellular domain of BCMA or by silver staining (Figure 14B). 
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The molecular weight of sBCMA detected by immunoblot and silver staining was about 6 
kDa. This roughly corresponded to the size of the extracellular domain BCMA (54 amino 
acids, calculated MW 5.8 kDa). The full-length receptor is constituted of 184 amino acids 
with an expected calculated MW of 20 kDa) 
 
 
Figure 14. Immunoprecipitation of sBCMA reveals M.W. around 6kDa. sBCMA was 
immunoprecipitated from supernatant of plasmacytoma cells (A, lanes 1, 2), serum (A, lane 
3), and from supernatant of native B cells cultured with CD40L plus IL-21 (A, lane 4) with 
anti-BCMA mAb A7D12.2 (A, lanes 1 and 4), the mAb C12A3.2 (A, lane 2), or goat-anti-
BCMA (A, lane 3). Western blot for BCMA (A) and silver staining of sBCMA 
immunoprecipitated from plasmacytoma supernatant (B) was performed. IgH: 
Immunoglobulin heavy chain; IgL: Immunoglobulin light chain. Modified from Laurent, 
Hoffmann et al. 2015. 
 
 
4.3.2 Mass spectrometry analysis of sBCMA 
 
sBCMA was concentrated by immunoprecipitation and obtained by acidic elution. The eluate 
was then desalted and concentrated using C18 microcolumns. Then two approaches were 
followed. A) The material was digested in solution by trypsin or chymotrypsin and analyzed 
by mass spectrometry (LTQ Orbitrap XL). B) The i.p. material was separated via an SDS gel, 
silver stained (Chevchenko protocol) and the band corresponding to BCMA as detected by 
Western blot was excised and analyzed by mass spectrometry (LTQ Orbitrap XL). 
Mass spectrometry revealed that sBCMA comprised not only the complete extracellular 
domain, but also part of the transmembrane region, indicating that it is released or shed by an 
intramembranous protease (Figure 15A). The peptides identified are listed in the table below 
(Figure 15B). 
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Figure 15. sBCMA comprises the extracellular domain and part of the transmembranous 
region of BCMA. (A) The band at 6 kDa (from Fig. 2.1.b) and sBCMA obtained by 
immunoprecipitation were analyzed by mass spectrometry. Amino acid sequences of BCMA 
and peptides identified after tryptic (blue) or chymotryptic (red) digestion are shown. No 
peptide was detected with a C-terminal amino acid that was not a site for either tryptic or 
chymotryptic cleavage, indicating that the precise cleavage site of γ-secretase within the 
membrane needs to be identified.(B) Identified peptides of mass spectrometry analysis of 
sBCMA. Modified from Laurent, Hoffmann et al. 2015. 
 
4.4 Direct shedding of sBCMA by γ-secretase 
 
4.4.1 γ-secretase inhibitor DAPT inhibits sBCMA generation and increases BCMA cell 
surface expression 
 
BCMA receptor is a single pass type-III oriented transmembrane protein, thus featuring an 
extracellular N-terminus while lacking a signal peptide. Since sBCMA contains part of the 
transmembrane domain, the intramembranous γ-secretase appeared to be a prime protease 
candidate. We therefore tested the γ-secretase inhibitor DAPT (N-[N-(3,5-
Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester) on sBCMA generation and 
BCMA surface expression on our plasmacytoma cell line and on activated human B cells. In 
addition, we analyzed in parallel the effects of the metalloprotease inhibitor TAPI-1. 
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We observed that overnight DAPT treatment almost completely abrogated even at low 
concentrations the release of sBCMA in a plasmacytoma cell line in a dose-dependent manner 
(Figure 16B), while simultaneously increasing surface expression of BCMA (Figure 16A). 
In contrast, TAPI-1 had little or no effect on sBCMA release and surface expression (Figure 
16C, D). Toxicity-induced, unspecific reduction of sBCMA shedding and BCMA surface 
expression was observed at a vehicle concentration of 0.5 % DMSO, which corresponds to 50 
µM TAPI-1. 
 
 
Figure 16. γ-secretase inhibitor DAPT blocks BCMA shedding in plasmacytoma cells. The 
human plasmacytoma cell line JK-6L was incubated overnight with DAPT or TAPI-1. Surface 
expression of BCMA was measured by flow cytometry (A, C) and sBCMA in the supernatant 
was determined by ELISA (B, D). Error bars indicate the SEM of technical replicates, 
representative of 3 experiments. Modified from Laurent, Hoffmann et al. 2015. 
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Figure 17 
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Figure 17. γ-secretase inhibitor DAPT reduces release of sBCMA and enhances surface 
expression of BCMA on activated human B cell. (A, B) Human B cells were differentiated to 
Ig-secreting cells via CD40L+IL-21. (A) Release of sBCMA upon treatment with DAPT or 
TAPI-1 was measured by ELISA. sBCMA release was normalized to the amount of sBCMA 
shed under vehicle conditions, which was set as 100%. Combined data of 3 independent 
experiments (mean±SEM). (B) These activated primary human B cells were sub grouped 
based on expression of CD27 and CD38. A high surface expression of BCMA was seen on the 
CD27++CD38+ subset. Surface expression of BCMA was enhanced by DAPT treatment, while 
TAPI-I had little effect. (C, D) Human PBMC were stimulated with R848+IL-2 for 7 days. (C) 
Release of sBCMA upon treatment with DAPT or TAPI-1 was measured by ELISA. sBCMA 
release was normalized to the amount of sBCMA shed under vehicle conditions, which was 
set as 100%. Combined data of 3 independent experiments (mean±SEM). (D) High surface 
expression of BCMA was seen on the CD19+CD38+ subset; this was further enhanced by 
DAPT, while TAPI-I had little effect (Laurent, Hoffmann et al. 2015). 
 
 
To determine the effect of γ-secretase on human primary B cells, PBMCs were obtained from 
healthy donors. Native B cells were isolated and differentiated into ISCs with CD40L and IL-
21 as described earlier. In a second approach total PBMCs were also activated by stimulation 
with the TRL7/8 agonist resiquimod (R848) and IL2, which resulted in the apparition of IgG 
secreting cells. Cells were then washed and stimulated overnight with DAPT and TAPI-1. 
Similar as in the plasmacytoma cell line, we found a dose-dependent decrease of the sBCMA 
release (Figure 17A) and an increased BCMA surface expression (Figure 17B), upon DAPT 
treatment, while only minimal effect was seen upon TAPI-1 treatment (Figure 17 C-D). The 
DAPT effect was already observed at the low working concentration of 0.1 µM. 
Moreover, we compared the effect of transition (LY-411575-I, LY685,458) and non-
transition state (DAPT, RO4929097) inhibitors of the γ-secretase on BCMA shedding from 
human B cells. Human PBMCs were first stimulated with R848+IL2 for 7 days, then CD19+ 
B cells were positively selected and cultured overnight in the presence of these γ-secretase 
inhibitors. We found that RO4929097, LY-411575-I, and LY685,458 had similar effects as 
DAPT on the shedding of mBCMA as seen in FACS and ELISA (Figure 18A, B).  
Further, to formally verify that the stereoisomer SSR of LY-411575, referred as LY-411575-I, 
was also a γ-secretase inhibitor, we transfected HEK293T cells with human BCMA or with 
the established γ-secretase substrate C99 and treated them overnight with either DAPT (1 
µM), with LY-411575-I (100 nM) or with the appropriate vehicle. As expected LY-411575-I 
inhibited both C99 and BCMA shedding by the γ-secretase (Figure 18C, D). 
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Figure 18. Different types of γ-secretase inhibitors block the release of sBCMA. Human 
PBMCs were stimulated with R848 and IL-2 for 7 days and then CD19+ B cells were 
positively selected. (A) After an overnight culture with the indicated γ-secretase inhibitors the 
released sBCMA in the supernatant was measured by ELISA, (mean±s.e.m. of three 
experiments) (B) After an overnight culture with the indicated γ-secretase inhibitors, BCMA 
surface expression was determined after gating on CD19+CD38+ Ig-secreting cells, which 
represented in this experiment about 50% of the CD19+ cell population.. The concentrations 
of the γ-secretase inhibitors were DAPT 1 µM, RO4929097 10 µM, LY-411575-I 100 nM and 
LY685,458 1 µM. Representative of 3 independent experiments, mean±s.e.m.. (C-D) 
HEK293T cells were transfected with human BCMA or with the established γ-secretase 
substrate C99 and treated overnight with either DAPT (1 µM), with LY-411575-I (100 nM) or 
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with the appropriate vehicle. Surface expression of BCMA or C99 was measured in by flow 
cytometry. (A) Surface expression of human BCMA or C99 upon DAPT and LY-411575-I 
treatment. Mean±s.e.m. of 6 replicates, *, p <0,05; **, p<0,01, unpaired t-test. (B) 
Representative histograms of BCMA and C99 surface expression upon DAPT (1 µM) and LY-
411575-I (100 nM) treatment. Modified from Laurent, Hoffmann et al. 2015. 
 
4.4.2 sBCMA cleavage is mediated by Presenilin-1 
 
To formally prove that sBCMA cleavage depends on the γ-secretase complex, we applied 
mouse embryonic fibroblast (MEF) cells derived from PS1/2 (PS-/-) double knockout mice. 
These PS1/2 deficient cells were first stably transduced with full length human BCMA and 
then stably transduced with either wt PS1 or a catalytically inactive D385A mutant PS1. 
Expression of wt PS1 strongly reduced surface expression of BCMA and resulted in about 15 
fold higher level of sBCMA in the supernatant, while the enzymatically inactive D385 had no 
effect (Figure 19A-D). Expression and endoproteolysis of PS1 in these transfectants was 
formally shown by immunoblotting of cell lysates with antibody PSEN1 (and maturation of 
nicastrin (NCT) by immunoblotting with antibody N1660 (Figure 19C). 
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Figure 19. Release of sBCMA requires active presenilin. (A-D) Presenilin-deficient MEF 
cells (PS-/-) were transduced with BCMA (PS-/- BCMA) and then with wild-type PS1 (PS-/- 
BCMA PS1) or with a catalytically inactive mutant (PS-/- BCMA PS1-D385A). BCMA 
surface expression (A,B) and sBCMA release (D) was determined. In (A) a representative 
experiment is shown, in B,D mean±SEM of four independent experiments is given 
(respectively p=0.0313 and p=0.0033, *, p <0,05; **, p<0,01 paired t-test). (C) Cells used in 
a, b, d were analyzed by immunoblotting for expression of full-length PS1 (PS1holo), for 
autoendoproteolysis of PS1 generating a C-terminal fragment (PS1CTF) reflecting an active 
state of the γ-secretase, for maturation of nicastrin (NCT) and for full-length BCMA (BCMA).  
(Laurent, Hoffmann et al. 2015) 
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4.4.3 Shedding of BCMA by γ-secretase occurs without prior N-terminal trimming and 
is length-dependent 
 
So far γ-secretase has been known to cleave the remaining c-terminal fragment of a membrane 
protein after shedding of its extracellular domain, but not to directly shed any membrane 
protein. Therefore we used an additional experimental approach to confirm that the γ-
secretase directly cleaved BCMA without prior N-terminal trimming by another protease. 
A human BCMA clone with an N-terminal FLAG-tag was constructed and transiently 
transfected into HeLa cells. sBCMA was detected in the supernatant of cells transfected with 
either BCMA-FLAG or BCMA alone to a similar extent as seen by ELISA using anti-BCMA 
for coating and anti-BCMA for detection (Figure 20). When we used anti-FLAG for coating 
and anti-BCMA for detection, we found sBCMA-FLAG in the supernatant of the BCMA-
FLAG transfectants (Figure 20B). The concentration of sBCMA-FLAG decreased when 
increasing levels of DAPT were added to the cells. The extent of DAPT mediated down-
regulation of sBCMA and sBCMA-FLAG was comparable (Figure 20A,B). These results 
strongly suggest that γ-secretase directly cleaves BCMA-FLAG without prior N-terminal 
trimming by another protease.  
 
BCMA has an unusual short extracellular domain (54 aa). To test whether BCMA shedding 
might be length-dependent, we doubled its extracellular part artificially obtaining a variant 
called BCMA-BCMA with an extracellular part of 108aa. We transfected wildtype BCMA 
and the BCMA-BCMA construct into HEK cells. While the γ-secretase inhibitor DAPT 
strongly enhanced the surface expression of mBCMA and blocked the release of sBCMA 
after transfection of wild-type BCMA, DAPT had little or no effect on surface expression or 
release of hBCMA-BCMA (Fig. 20 C, D and E). Thus, the short extracellular domain of 
mBCMA facilitates its direct cleavage by γ-secretase 
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Figure 20. Release of sBCMA occurs without prior N-terminal trimming and is length-
dependent. (A-B). HeLa cells were transfected with plasmids coding for full-length BCMA or 
BCMA with an N-terminal-FLAG and then cultured with increasing amounts of the γ-
secretase inhibitor DAPT (0.02 µM, 0.1 µM, 0.5 µM). 24h after transfection supernatants 
were harvested and the released sBCMA was analyzed by ELISA. In (A) ELISA wells were 
coated with anti-BCMA and in (B) with anti-FLAG or a control IgG (anti-MOG 8.18 C5), 
both were developed with anti-BCMA. Schemes of the ELISAs are shown on the right. 
Combined data of 2 independent experiments (mean±SEM). (C-E) Human BCMA wild type 
(wt) or BCMA-BCMA with a doubled extracellular domain of BCMA were transfected into 
HEK293T cells. (C,D) Surface expression of BCMA was determined in the absence or 
presence of the γ-secretase inhibitor DAPT (1 µM). (D) shows the combined data of 3 
experiments (p=0.0049,unpaired t-test. (E) shows the effect of DAPT on the released sBCMA 
after transfection with BCMA wt or BCMA-BCMA (mean±SEM. of 3 experiments), 
p=0.0081,unpaired t-test. Modified from Laurent, Hoffmann et al. 2015. 
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4.5 Functional consequences of sBCMA  
 
4.5.1 Inhibition of sBCMA shedding increases APRIL-binding to cell surface and 
increases APRIL-mediated induction of HLA-DR and NF-κB activation in vitro  
 
In order to assess the consequences of sBCMA shedding to the binding of APRIL to the cell 
bound BCMA we added APRIL-FLAG to plasmacytoma cells, which had been preincubated 
with or without DAPT overnight. Cell bound APRIL-FLAG was then detected by flow 
cytometry using an anti-FLAG antibody. We observed that the enhanced BCMA expression 
after DAPT was accompanied with an increased binding of its ligand APRIL-FLAG (Figure 
21A).  
To analyse whether DAPT-mediated increased BCMA expression was accompanied by 
enhanced cellular responsiveness to APRIL we used two read-out systems, induction of HLA-
DR on human B cells or NF-κB activation in BCMA-transfected HEK cells, and obtained 
similar results. In BCMA transfected HEK293T cells, DAPT increased NF-κB activation 
induced via APRIL and also via BAFF (Figure 21B). As APRIL stimulation via BCMA has 
been described to lead to higher MCH-II expression (Yang, Hase et al. 2005) in mice, we 
looked at HLA-DR expression upon APRIL stimulation in R848/IL2 primary activated 
human B. We noted that stimulation of these primary activated human B cells with APRIL led 
to higher surface expression of HLA-DR, which was further enhanced by the γ-secretase 
inhibitor DAPT, in particular at suboptimal concentrations of APRIL. This effect was slight, 
but significant, as seen in 6-8 replicates with different concentrations (Figure 21C).  
Figure 21. Inhibition of sBCMA shedding increases APRIL-binding to cell surface and 
limits APRIL-mediated induction of HLA-DR and NF-κB activation in vitro. (A) BCMA 
ligand APRIL-FLAG was added to plasmacytoma cells after pretreatment with DAPT and its 
binding was analyzed with anti-FLAG mAb. (B) HEK293T cells were transfected with full-
length BCMA or an empty vector and a luciferase-based NF-κB-reporter. DAPT, APRIL and 
BAFF were added as indicated and NF-κB activation was determined. (C) PBMCs were 
activated with R848+IL-2 for 7 days. The expression of HLA-DR on CD19+ cells was 
elevated by APRIL and this effect was further enhanced by DAPT. The respective isotype 
control stainings were not modified by the different stimuli (data not shown). A representative 
example is shown on the left. The effects might appear small, but the significance was 
elaborated in 6-8 independent replicates from 5 different donors and compiled data are 
shown on the right. (**, p<0.01; ****, p<0.0001 and ***, p<0.001, paired t-test). Modified 
from Laurent, Hoffmann et al. 2015. 
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4.5.2 sBCMA acts as a decoy receptor for APRIL and limits APRIL mediated B cell 
survival in vitro. 
 
To further investigate the biological implications of sBCMA we set out to determine whether 
the shed receptor remained able to bind APRIL or BAFF thus functioning as a decoy receptor. 
We established an ELISA, in which the anti-FLAG M2 mAb was used for coating in order to 
immobilize APRIL-FLAG or BAFF-FLAG on the ELISA plate. Then sBCMA from 
supernatant of HEK cells transfected with BCMA was added and incubated for 2 hours at 
room temperature. BCMA was detected as described above. We found that sBCMA bound 
APRIL, but not BAFF (Figure 22). This was different to membrane BCMA, which binds 
both APRIL and BAFF (Mackay and Schneider 2009). We found that the naturally occurring 
sBCMA also differed from recombinant BCMA-Fc, which binds both APRIL and BAFF 
(Figure 22).  
 
 
 
Figure 22. sBCMA binds APRIL. A scheme of the ELISA is shown on the left; it detects 
BCMA-APRIL-FLAG (left panel) or BCMA-BAFF-FLAG (right panel) complexes, but neither 
BCMA nor APRIL-FLAG nor BAFF-FLAG alone (*, p<0.05, paired t-test). sBCMA was 
derived from the supernatant of plasmacytoma cultured under serum-free conditions. 
Combined data of 3 independent experiments (mean±SEM). Modified from Laurent, 
Hoffmann et al. 2015. 
 
 
These differences between sBCMA and BCMA-Fc were also seen in NF-κB reporter assays: 
in HEK cells transfected with BCMA, APRIL-mediated NF-κB activation was blocked by 
both sBCMA and BCMA-Fc, while BAFF-mediated activation via membrane bound BCMA 
was suppressed only by BCMA-Fc, not by sBCMA (Figure 23A). Since APRIL can signal 
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via membrane bound BCMA and TACI we transfected HEK cells also with TACI. These 
experiments showed that sBCMA inhibited APRIL, but not BAFF-mediated signaling via 
TACI (Figure 23B). sBCMA thus acts as APRIL-specific decoy.  
 
We aimed to analyse whether sBCMA could limit APRIL-mediated survival of activated B 
cells. To measure APRIL-induced survival, mouse B cells, magnetically isolated from spleen, 
were cultured in 96-well microtiter plates, which were precoated with anti-IgM. APRIL-
FLAG was added for 48h and cross-linked with anti-FLAG mAb antibody. Supernatants 
generated by HEK293T cells that had been transfected with either full-length BCMA or an 
empty control vector and therefore either contained sBCMA or did not, were added at a final 
sBCMA concentration of 200 ng/ml and 400 ng/ml. Cell survival was quantified by flow 
cytometry and APRIL-induced survival was calculated as followed: 100 x [(cell survival in 
presence of APRIL – cell survival without APRIL) / cell survival without APRIL]. We 
observed a dose-dependent inhibition of APRIL-induced survival by sBCMA. (Figure 23C).  
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Figure 23. sBCMA is an APRIL-specific decoy. (A) HEK293T cells were transfected with 
BCMA and activated with APRIL (left panel) or BAFF (right panel). sBCMA (50 and 200 
ng/ml) was applied as indicated. sBCMA and control supernatant were obtained as 
mentioned above. BCMA-Fc (50 and 200 ng/ml) was used as a positive control. Combined 
data of 3 independent experiments (mean±SEM, *, p<0.05; **, p<0.01 paired test). (B) 
HEK293T cells were transfected with TACI and activated with APRIL or BAFF as indicated. 
sBCMA (50 and 200 ng/ml) was applied as indicated. sBCMA and control supernatant were 
obtained from HEK293T cells that had been transfected with full-length BCMA or an empty 
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control vector. BCMA-Fc (50 and 200 ng/ml) was used as a positive control. Combined data 
of 3 independent experiments (mean±SEM, *, p<0.05, paired t-test). (C) Murine B cells were 
activated via anti-IgM and cultured for 2 days with APRIL in the presence or absence of 
sBCMA (200 and 400 ng/ml). APRIL-induced survival was calculated as described in 
material and methods. sBCMA was obtained from supernatant from HEK293T cells 
transfected with full-length BCMA (black bars). Control supernatant was obtained after 
transfection with an empty vector (white bars). sBCMA significantly inhibited APRIL 
mediated survival (***, p<0.001 and **, p <0.01, paired t-test). Combined data of 6 
independent experiments (mean± SEM). Modified from Laurent, Hoffmann et al. 2015.  
 
4.6 γ-secretase regulates BCMA shedding in vivo 
 
4.6.1 γ-secretase inhibitors enhance BCMA expression of mouse cells in vitro. 
 
To address the question whether sBCMA cleavage occurs in mice B cells, murine 
plasmacytoma cells J558L were treated with γ-secretase inhibitors DAPT, LY-411575-I and 
the respective vehicle controls overnight. Treatment with both inhibitors resulted in a similar 
strong increase in BCMA cell surface expression (Figure 24).   
Figure 24. Increased BCMA expression in a murine plasmacytoma cell line upon treatment 
with γ-secretase inhibitors DAPT and LY-411575-I. J588L plasmacytoma cells were treated 
over night with either DAPT (left panel) or the γ-secretase inhibitor LY-411575-I (right 
panel). BCMA surface expression was measured by flow cytometry. 
 
 
Results 
74 
 
4.6.2 γ-secretase regulates BCMA and plasma cells in vivo 
 
To address the question whether cleavage of mBCMA by γ-secretase occurred also in vivo, 
we used two different mouse models. First, we immunized mice with ovalbumin (OVA) and 
LPS to induce a T-dependent immune response and plasma cell differentiation (Figure 25). 
Treatment 9 days later with the γ-secretase inhibitor LY-411575-I for one day resulted in an 
enhanced surface expression of mBCMA in CD138+ plasma cells in spleen and bone marrow 
(Figure 26). In the absence of a γ-secretase inhibitor, mBCMA was barely detectable on the 
surface of murine plasma cells, in line with previous observations (Peperzak, Vikstrom et al. 
2013).  
 
 
 
 
 
Figure 25. Immunization and treatment protocol. Two months old C57/BL6 mice were 
immunized intraperitoneally with 100 µg ovalbumin and 10 µg LPS in alum and sacrificed 10 
days later. Immunized mice received an intraperitoneal dose (10 mg/kg) of the γ-secretase 
inhibitor LY-411575-I on day 9, followed by another dose 6 hours before sacrifice. 
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Figure 26. γ-secretase regulates surface display of BCMA in vivo. Immunized mice were 
treated with the γ-secretase inhibitor LY-411575-I and the surface display of BCMA in 
splenocytes (A) or bone marrow (B) was measured by flow cytometry. BCMA expression on 
gated B220+CD138+ cells is shown, a representative example (left) and compiled data from 
all 17 analyzed animals (mean, ***, p<0.001, unpaired t-test) (right). The black symbols on 
the right indicate the samples shown on the left. Closed histograms indicate isotype controls. 
Modified from Laurent, Hoffmann et al. 2015. 
 
As a second model, we used NZB/W mice, a widely used murine SLE model, in which 
germinal centers can develop spontaneously (Luzina, Atamas et al. 2001). We noticed that 
also in this model, one day of treatment with the γ-secretase-inhibitor LY-411575-I was 
sufficient to induce an increased surface expression of BCMA on plasma cells in the spleen 
and bone marrow (Figure 27A). In order to distinguish between short-lived and long-lived 
plasma cells, mice were fed bromodeoxyuridine (BrdU). We found that inhibition of γ-
secretase for one day enhanced mBCMA both on BrdU+ plasma cells, or short-lived 
plasmablasts, and on BrdU- long-lived plasma cells in bone marrow and spleen (Figure 27A).  
To analyse the effect on long-term treatment with γ-secretase inhibitors on the mBCMA and 
plasma cells survival, we treated NZB/W mice with LY-411575-I for 7 days. As expected, we 
observed an enhanced expression of mBCMA on BrdU+ and BrdU- plasma cells in bone 
marrow and spleen (Figure 27B). Moreover, this prolonged treatment period enhanced the 
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number of BrdU+ and BrdU- plasma cells in the bone marrow, but not in the spleen (Figure 
27C). In the spleen, the absolute number of BrdU+ plasma cells per organ decreased, but not 
their relative number (Figure 27D). In the bone marrow treatment with the γ-secretase 
inhibitor increased both the absolute and also the relative number of plasma cells (Figure 
27D). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. γ-secretase regulates plasma cells in mice. (A) NZB/W mice pretreated with BrdU 
received the γ-secretase inhibitor LY-411575-I (red) or vehicle (blue) for one day. Surface 
expression of BCMA on all CD138+ plasma cells (PC) and the BrdU+ and BrdU- PC 
subgroups in spleen and bone marrow (BM) was determined by flow cytometry (mean, ***, 
p<0.001; **, p <0.01, unpaired t-test) . (B-D) 7 days treatment of NZB/W mice with LY-
411575-I (red) or vehicle (blue). (B) BCMA surface expression in the spleen and bone 
marrow (BM) on B220, and BrdU+ and BrdU- plasma cells was determined. (C) Absolute 
number of plasma cells, BrdU+ and BrdU- plasma cells in spleen and bone marrow. (D) 
Frequency (% of all cells in the organ) of plasma cells in spleen and bone marrow. Compiled 
data from 10 analysed animals per group (mean,*, p<0.05; **, p<0.01; ***, p<0.001; ****, 
p<0.0001, unpaired t-test). Modified from Laurent, Hoffmann et al. 2015. 
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5 DISCUSSION  
 
5.1 sBCMA as a novel biomarker for B cell driven autoimmunity  
 
A hallmark in MS is the persistence of plasma cells inside the CNS compartment, which is 
accompanied by local Ig production (Meinl, Krumbholz et al. 2006; von Budingen, Bar-Or et 
al. 2011). A possible explanation for this would be the local production of BAFF and APRIL 
by astrocytes leading to B cell fostering niches in the inflamed CNS inside the brain 
compartment (Krumbholz, Theil et al. 2005). BCMA being mainly expressed by plasma cells, 
we aimed to address the question whether this plasma cell fostering milieu in the CNS of MS 
patients would translate into altered sBCMA levels.  
We therefore measured sBCMA in CSF of patients with multiple sclerosis, neuroborreliosis 
and other non-inflammatory neurological diseases and found that sBCMA was indeed 
elevated in the CSF of MS patients and that the increased levels closely correlated to the local 
Ig production. Increased sBCMA levels were also detected in CSF of patients with 
neuroborreliosis indicating that far from being a disease specific marker, increased levels of 
sBCMA rather indicates an intrathecal B cell driven immune response. In order to assess if 
these findings could be extrapolated to systemic B cell driven autoimmune diseases, we went 
on analysing sBCMA in serum of patients with SLE. In this disease, activation of the B cell 
compartment typically goes along with elevated levels of BAFF. We observed that serum 
sBCMA levels were elevated in SLE patients and that these levels closely correlated to the 
disease activity. Further in vitro experiments showed that native human B cells produce 
sBCMA upon differentiation into Ig-secreting cells thus pointing towards plasma cells in the 
CNS as a possible source for sBCMA in the CSF of MS patients.  
 
The significance of soluble receptors as prognostic or therapeutic marker has been already 
well documented for several receptors, in particular for soluble TNF-receptors I and II. For 
example, in acute and systemic inflammatory responses, including bacterial sepsis (Froon, 
Bemelmans et al. 1994) and falciparum malaria (Kern, Hemmer et al. 1992), high serum 
sTNFR usually correlate with disease severity and mortality. A recent study from our group 
has shown that TACI receptor, which can bind both APRIL and BAFF, was shed by the 
metalloproteinase ADAM10 and resulted in an endogenous soluble TACI receptor which 
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acted as a decoy receptor for BAFF and APRIL. Similarly to BCMA, elevated sTACI levels 
were found in MS and SLE (Hoffmann, Kuhn et al. 2015). 
Histological studies have shown that there is a clear heterogeneity between individual MS 
patients regarding the immunopathological patterns of disease seen in MS lesions. While 
some MS patients show lesions with T-cell/macrophage-associated patterns, other patient’s 
lesions display antibody/complement-associated demyelination. The development of 
biomarkers, which would allow us to distinguish between the underlying immunopathological 
mechanisms, would be of tremendous clinical importance as it would enable to predict 
therapeutic response. Based on our results, sBCMA reflects activation of the BAFF/APRIL 
pathway and thus shows the promising features of a biomarker for B cell driven autoimmunity 
in MS and SLE and could serve as a further paraclinical marker for disease activity in SLE. 
Further studies will be needed to assess if sBCMA in MS patients can serve as a prognostic 
biomarker for disease activity and therapeutic response, in particular to B cell targeting 
therapies.  
 
5.2 Direct cleavage of BCMA by γ-secretase 
 
The generation of soluble receptors by proteolytic cleavage of the extracellular domain 
constitutes a highly conserved and common regulatory mechanism of immunity and 
inflammation with notorious examples including TNFR1, TNFR2, CD30, CD40, and IL-6Rα. 
So far, generation of soluble receptors by shedding required the proteolytic cleavage of the 
extracellular domain by a metalloproteinase. This first cleavage was believed to be a 
prerequisite for further cleavage by the intramembranous γ-secretase (Kopan and Ilagan 2004; 
Lichtenthaler, Haass et al. 2011). 
In our work we found that BCMA however, is directly cleaved by the γ-secretase without any 
previous cleavage by a metalloproteinase. First, treatment of sBCMA producing cells with 
different γ-secretase specific inhibitors almost completely abrogates BCMA shedding and 
highly increases the cell surface expression of BCMA. Moreover, using MEF cells deficient 
for both PS1 and PS2 (PS-/-) transduced with human BCMA and rescued with either wt PS1 
or a deficient form of PS1 (D385), we showed that a full-functioning PS1 unit is necessary for 
BCMA shedding. The direct shedding of BCMA without previous cleavage was confirmed by 
ELISA using HELA-cells transfected with human BCMA containing a N-terminal-FLAG tag.  
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This constitutes a novel proteolytic feature of the γ-secretase, as until now this enzyme 
complex has not been known to act on intact membrane proteins. γ-secretase does not cleave 
at a specific aa sequence, but its activity seems to be influenced by the length of the 
extracellular domain: little processing occurred when the extracellular domain exceeded 100 
aa, while extracellular parts of about 50 aa permitted effective γ-secretase cleavage (Struhl 
and Adachi 2000). In line with these previous results we found that the artificial increase of 
the extracellular domain of BCMA resulted in a striking reduction of shedding. Direct 
cleavage of BCMA by γ-secretase is thus presumably facilitated by the unusually short 
extracellular domain of native BCMA (54 aa). BCMA is so far the only known direct 
substrate of γ-secretase. Screening for substrates of the γ-secretase, focussing on proteins with 
short extracellular domains, could help identify other direct γ-secretase substrates in the 
future. 
 
5.3 Functional consequences of BCMA shedding 
  
Soluble receptors can prevent binding of a cytokine to its membrane-bound receptors, thus 
inhibiting signal transduction and biological activity. They are thus generally regarded as 
antagonists for their ligands. The fact that both the membrane–bound and soluble receptors 
bind the same cytokine implies that competition takes place between the two receptor forms. 
It is essential to stress that the concentration of a soluble receptor required to block biological 
activity is dependent on a complex set of variables, including the relative affinities and 
binding profiles of membrane-bound receptors versus soluble receptors, the number of 
membrane-bound receptors on the target cells, cytokine and soluble concentration and the 
fraction of membrane-receptors that need to be occupied to result in a biological response. 
Beside the decoy function of the shed receptors, the release through proteolytic cleavage 
constitutes a common mechanism in which the cell evades the effects of a specific cytokine 
by reducing the number of membrane-bound receptors available. In this regard the overall 
physiological effect of soluble receptors is likely to be the one of a negative feed-back 
mechanism.  
In addition to this regulatory aspect, which can be found enhanced in pathological states, 
mutations that affect the shedding mechanism in itself can lead to disease. A famous example 
is TNFR1. In humans, different mutations on the TNFR1 gene, that associate with impaired 
receptor shedding, are linked to a group of dominantly inherited autoinflammatory syndromes 
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named TRAPS (McDermott, Aksentijevich et al. 1999). The physiological role of TNFR1 
shedding was explored in vivo with a knock-in mouse expressing a mutated non-sheddable 
TNFR1. These mice presented spontaneous autoinflammatory reactions as well as an 
enhanced susceptibility to experimental autoimmune encephalitis (Xanthoulea, Pasparakis et 
al. 2004). More recently, functional studies, regarding a single nucleotide polymorphism in 
the TNFRSF1A gene that encodes TNFR1 and constitutes a genetic risk factor for MS, 
showed that this MS risk allele directs, by modified alternative splicing, expression of a new 
soluble TNFR1 (Gregory, Dendrou et al. 2012).  
 
 
5.3.1 BCMA shedding modulates APRIL-induced signaling 
 
Being confronted to this novel soluble form of BCMA, we aimed to get further insights into 
the functional relevance of BCMA shedding. Soluble cytokine receptors, which either reduce 
or promote cytokine signaling, are important regulators of inflammation and immunity. Our 
findings show that inhibition of BCMA shedding by the γ-secretase leads to an increased 
surface expression of BCMA, which in turn leads to an enhanced APRIL- and BAFF-binding 
to the cell surface and increased NF-κB activation. Taken together these results show that 
shedding of BCMA can regulate APRIL and BAFF-induced signaling. Similar to other 
soluble receptors, the decrease of the number of BCMA on the cell surface through shedding 
acts as a down-modulation mechanism, thus preventing signal generation by APRIL and 
BAFF. 
 
5.3.2 sBCMA is a new decoy receptor for APRIL 
 
If a soluble receptor retains its capacity to bind it(s) ligand(s), it may act as a decoy receptor 
by preventing further binding of the ligands to membrane bound receptors and thus reducing 
the pool of biological active ligand in the system. In our work we found evidence for such a 
decoy function of sBCMA. Indeed, in vitro a NF-κB assay and a B cell proliferation assay 
demonstrated that sBCMA was able to bind and inhibit APRIL-mediated effects, while no 
binding and no inhibition of BAFF was observed. These findings differ from the binding 
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profile of membrane-bound BCMA and the soluble fusion protein BCMA-Fc, which can bind 
both. 
One possible explanation for this difference in binding profile between sBCMA and BCMA-
Fc would be a strong gain of avidity of the dimerization state of BCMA in BCMA-Fc. 
Binding assays showed an avidity contribution of dimeric versus monomeric recombinant 
BCMA, which resulted in a more then 1000-fold increase in apparent affinity of BCMA 
binding to BAFF (Day, Cachero et al. 2005). 
It might appear at first sight paradoxical that sBCMA, which shows features of a decoy as we 
showed in this study, is elevated in autoimmune diseases involving B cells and antibodies. 
However increased levels of sBCMA, produced by locally or systemically accumulating Ig-
secreting cells, should be considered as a feed-back inhibitory mechanism that is not 
sufficient to completely down-regulate the immune response. Similar observations have 
already been made with sTNFR in SLE. In spite of being a decoy, sTNFR1, is elevated in 
SLE where it correlates with disease activity and is considered as a disease activity marker 
(Aderka, Engelmann et al. 1992; Heaney and Golde 1998; Xanthoulea, Pasparakis et al. 
2004). 
Other possible functions of sBCMA, beyond the inhibitory aspects of sBCMA, include 
additional agonistic effect and are yet to be explored. Indeed, some soluble receptor such as 
IL6-receptor are involved in trans-signaling mechanisms, by which the complex formed by 
sIL-6Rα and IL-6, can bind to a membrane-bound signal transducing subunit (gp130) on cells 
which do not express IL-6R and are unresponsive to IL-6 (Rose-John 2012). Furthermore, it 
has been reported that some soluble receptors including sTNF-R and sIL-4R potentiate the 
activity of their own cytokines in vivo under certain condition (Ma, Hurst et al. 1996). The 
underlying mechanisms involve the formation of cytokine/soluble receptor complexes that 
can result in increased molecular stability and prolonged half-life. 
Finally, the remaining intracellular part of the receptor, the C-terminal fragment after γ-
secretase cleavage, can be involved in further intracellular signaling by translocating into the 
nucleus where it can modulate gene expression as it has been described for NOTCH- pathway 
(Schroeter, Kisslinger et al. 1998; De Strooper, Annaert et al. 1999).  
The existence of these additional functions in case of BCMA shedding is still unknown and 
should be investigated in future. 
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5.3.3 In vivo relevance of BCMA shedding 
 
Our in vitro findings support the existence of a new regulatory feature within the 
BAFF/APRIL pathway. In order to investigate the physiological relevance of BCMA 
shedding, we treated wild type mice with a γ-secretase inhibitor, and observed, similarly to 
our in vitro results, an increase of BCMA expression on the cell surface. These short-term 
applications of a γ-secretase inhibitor revealed that γ-secretase regulates the amount of BCMA 
on the surface in vivo. To get further insights into the in vivo consequences of BCMA 
shedding, NZB/W mice, a widely used murine SLE model, were treated with a γ-secretase 
inhibitor. This revealed that γ-secretase inhibition increased the number of plasma cells in the 
bone marrow. Interestingly, in the spleen, we observed no increase in plasma cell number 
upon γ-secretase inhibitor treatment, even though surface BCMA was upregulated on plasma 
cells, as seen in the bone marrow.  
Based on our previous studies, the increased number of plasma cells in the bone marrow after 
γ-secretase inhibition is at least partially explained by the enhanced presence of mBCMA, 
since mBCMA mediates the induction of the survival protein Mcl-1 in bone marrow plasma 
cells (O'Connor, Raman et al. 2004; Peperzak, Vikstrom et al. 2013). Regarding, the 
differential effect of γ-secretase inhibition on the plasma cell number in spleen and bone 
marrow, a possible explanation can be given by the previous observation that BCMA induced 
high expression of Mcl-1 in bone marrow but not in spleen plasma cells. Also, BCMA-/- mice 
had reduced plasma cell numbers in the bone marrow, but not in the spleen (Peperzak, 
Vikstrom et al. 2013). 
Together our result show that in vivo inhibition of the BCMA shedding by γ-secretase 
enhances BCMA surface expression in plasma cells and leads to an increase number of 
plasma cells in the bone marrow. This increased survival of plasma cells is likely mediated by 
APRIL and due to the enhanced surface expression of BCMA (Figure 28). 
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Figure 28. Functional consequences of BCMA shedding by γ-secretase. Left: An active γ-
secretase cleaves BCMA. This reduces the number of membrane-bound BCMA molecules and 
releases sBCMA which binds its ligand APRIL functioning as a decoy. Right: γ-secretase 
inhibitors (GSI) result in elevated BCMA on the surface and increased APRIL-mediated 
activation and survival. Modified from Laurent, Hoffmann et al. 2015. 
 
 
Long-term application of γ-secretase inhibitors in vivo would be required to analyse the effect 
of inhibition of BCMA shedding on disease course. Unfortunately, this would not allow 
specific conclusions about the long-term consequences of sBCMA inhibition, because the γ-
secretase, through its effect on a broad range of substrate including NOTCH-receptors, 
regulates multiple effects in the immune system such as Th1 differentiation (Minter, Turley et 
al. 2005), T cell lineage commitment (Radtke, MacDonald et al. 2013), maintenance of 
marginal zone B cells (Simonetti, Carette et al. 2013), B cell activation (Yagi, Giallourakis et 
al. 2008), and survival of GC B cells (Yoon, Zhang et al. 2009). A further limitation of long-
term treatment with γ-secretase inhibitors is the associated gastrointestinal toxicity, likely 
associated with the inhibition of NOTCH-cleavage. 
The generation of a transgenic mouse displaying a non-sheddable BCMA receptor would 
avoid any NOTCH-associated toxicity and allow a most extensive study of the in vivo 
relevance of BCMA shedding. An important limitation is the lack of consensus cleavage 
patterns of γ-secretase as well as the expected multiple cleavage sites, which would likely 
necessitate a complete transmembrane swapping.  
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5.3.4 Regulation of BCMA shedding 
 
The direct cleavage of BCMA by the γ-secretase poses the problem of the regulation of 
sBCMA generation. While ADAM proteases are subject to multiple regulatory mechanisms 
such as ligand binding, the limiting event of the intramembranous proteolysis by the γ-
secretase has so far been the first extracellular cut by a distinct protease. Several non-mutual 
exclusive regulatory mechanisms are likely to be involved in the regulation of BCMA 
shedding. 
This study shows that sBCMA release is a direct consequence of BCMA surface expression 
by human B cells upon differentiation into Ig-secreting cells. These results are consistent with 
the data of previous studies, which showed that BCMA expression is induced as memory B 
cells differentiate into plasma cells (Darce, Arendt et al. 2007). Membrane-bound BCMA is 
then shed by the γ-secretase. This shedding doesn’t require any additional activation or ligand 
binding. The γ-secretase being ubiquitously expressed and at state of knowledge constitutively 
active without any known cytokine stimulation, the main regulatory event is thus likely to be 
the expression of BCMA upon differentiation of B cells, i.e. within a chronic autoimmune 
process, into plasma cells. Naturally, we cannot exclude that this shedding can be further 
enhanced by yet unknown mechanisms.  
 
A second potential mechanism which could generate increased sBCMA levels would be the 
upregulation of BCMA expression on plasma cells. Previous studies have reported that 
plasma cells in SLE patients display enhanced surface BCMA expression in comparison to 
healthy controls (Kim, Gross et al. 2011). Accordingly we indeed found higher sBCMA levels 
in serum of SLE patients. As to which stimuli would lead to an increase BCMA expression on 
the cell surface by plasma cells, little is yet known. BCMA being mainly found in 
intracellular golgi-like structures, stimuli which would lead either to an upregulated 
transcription or to a translocation of intracellular BCMA to the cell surface can results in an 
enhanced surface BCMA expression and thus result in increased sBCMA levels.  
Finally, consideration should be given to the possibility of a specific regulation of the γ-
secretase activity. So far the limiting or regulating event to the intramembranous proteolysis 
by the γ-secretase has been the first extracellular cut by a distinct protease. These proteases, 
i.e. ADAM proteases, are subject to multiple regulation mechanisms such as ligand binding 
and inflammation. Since BCMA is directed cleaved by the γ-secretase, these usual regulation 
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mechanisms cannot apply and therefore other regulation mechanisms of the γ-secretase 
remain to be investigate.  
 
5.3.5 sBCMA in biological therapy 
 
The involvement of BAFF and APRIL in the pathogenesis of many autoimmune and 
oncological diseases is well established. These cytokines thus represent valid key target for 
biotherapeutical approaches. Soluble receptors such as sBCMA with the ability to inhibit 
specific cytokines may have the potential to significantly contribute to the treatment of such 
disease. In addition, they display lower immunogenicity, in contrast to murine anti-cytokine 
antibodies, that normally induce anti-mouse immunoglobulin responses in patients.  
Nevertheless, cytokine and their soluble receptors are involved in a complex regulated 
pathway with many targets. Therefore extensive knowledge of the target pathway is still 
required to avoid unexpected consequences, such as seen in the Atacicept in multiple sclerosis 
(ATAMS) trial. In this placebo-controlled, double-blind, 36-week, phase 2 trial, a 
recombinant humanized fusion protein containing the extracellular part of TACI, a receptor 
binding both BAFF and APRIL, was administrated to MS patients. Unexpectedly the therapy 
led to increased clinical disease activity, suggesting that the role of BAFF and APRIL in 
multiple sclerosis is more complex than previously expected. (Kappos, Hartung et al. 2014). 
These findings stand in contrast to the beneficial effect B cell depleting therapies in multiple 
sclerosis (Bar-Or, Calabresi et al. 2008; Hauser, Waubant et al. 2008; Kappos, Li et al. 2011) 
and reveal a yet not fully understood BAFF/APRIL pathway. 
 
In this regard, the generation of a recombinant BCMA receptor, displaying a similar APRIL 
specific binding profile to the endogenous sBCMA could offer several advantages. Previous 
studies showed that the BCMA dependent maintenance of long-lived PC is largely mediated 
via its main ligand APRIL (Belnoue, Pihlgren et al. 2008). Since those cells are believed to be 
the source of pathogenic auto-antibodies in several autoimmune diseases, the specific 
inhibition of APRIL could in its turn target long-lived plasma cells. The beneficial effect of an 
APRIL-specific antibody-mediated blockade was described in a murine SLE model (Huard, 
McKee et al. 2008). sBCMA could therefore serve as model for a future pharmacological 
agent blocking specifically APRIL. 
Discussion 
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Together, we found that BCMA is directly shed from plasma cells by γ-secretase and suggest 
that this shedding constitute a regulatory mechanism for plasma cell survival in the bone 
marrow. Furthermore shedding of BCMA could serve as a potential biomarker for B cell 
driven autoimmunity and could open ways for new therapeutic strategies. 
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